{"content":"<li class=\"n-box-item date-title\" data-end=\"1561435199\" data-start=\"1561348800\" data-txt=\"Monday, December 23, 2019\">Monday, June 24, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3473427\" data-ts=\"1561414246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GMDA\" target=\"_blank\">GMDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473427-gamida-cellminus-9_7-on-registration-of-34_7m-in-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gamida Cell -9.7% on registration of $34.7M in shares</a></h4><ul>   <li>Gamida Cell (NASDAQ:<a href='https://seekingalpha.com/symbol/GMDA' title='Gamida Cell Ltd.'>GMDA</a>) is <font color=\"red\">9.7% lower</font> on a registration to <a href=\"https://seekingalpha.com/filing/4542156\" target=\"_blank\">offer $34.7M worth of shares</a>.</li>    <li>That comes via RBC Capital markets, JMP Securities and Oppenheimer.</li>    <li>It expects net proceeds of about $27.7M (or $31.9M if underwriters exercise an overallotment option in full), to be used as follows: $15M-$20M to fund clinical development; about $5M-$10M to expand manufacturing, and the rest for general purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473427\" data-linked=\"Gamida Cell -9.7% on registration of $34.7M in shares\" data-tweet=\"$GMDA - Gamida Cell -9.7% on registration of $34.7M in shares https://seekingalpha.com/news/3473427-gamida-cellminus-9_7-on-registration-of-34_7m-in-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3473427-gamida-cellminus-9_7-on-registration-of-34_7m-in-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473422\" data-ts=\"1561412027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473422-ptc-sgen-cpt-and-invh-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTC, SGEN, CPT and INVH among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/PTC' title='PTC Inc.'>PTC</a> <font color=\"green\">+13.2%</font>. <a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a> <font color=\"green\">+12.5%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc.'>IGC</a> <font color=\"green\">+10.2%</font>. <a href='https://seekingalpha.com/symbol/RRD' title='R.R. Donnelley & Sons Company'>RRD</a> <font color=\"green\">+7.7%</font>. <a href='https://seekingalpha.com/symbol/ST' title='Sensata Technologies Holding plc'>ST</a> <font color=\"green\">+7.5%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/CPT' title='Camden Property Trust'>CPT</a> <font color=\"red\">-55.5%</font>. <a href='https://seekingalpha.com/symbol/INVH' title='Invitation Homes Inc.'>INVH</a> <font color=\"red\">-42%</font>. <a href='https://seekingalpha.com/symbol/EXPD' title='Expeditors International of Washington, Inc.'>EXPD</a> <font color=\"red\">-39.4%</font>. <a href='https://seekingalpha.com/symbol/FNF' title='Fidelity National Financial, Inc.'>FNF</a> <font color=\"red\">-30.7%</font>. <a href='https://seekingalpha.com/symbol/VOYA' title='Voya Financial, Inc.'>VOYA</a> <font color=\"red\">-22.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473422\" data-linked=\"PTC, SGEN, CPT and INVH among after hour movers\" data-tweet=\"$PTC $SGEN $IGC - PTC, SGEN, CPT and INVH among after hour movers https://seekingalpha.com/news/3473422-ptc-sgen-cpt-and-invh-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473422-ptc-sgen-cpt-and-invh-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473421\" data-ts=\"1561411697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473421-usana-xencor-get-lift-on-entry-to-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">USANA, Xencor get lift on entry to SmallCap 600</a></h4><ul>    <li>USANA Health Sciences (NYSE:<a href='https://seekingalpha.com/symbol/USNA' title='USANA Health Sciences, Inc.'>USNA</a>) is <font color=\"green\">up 6%</font> after hours, and Xencor (NASDAQ:<a href='https://seekingalpha.com/symbol/XNCR' title='Xencor, Inc.'>XNCR</a>) <font color=\"green\">up 5.1%</font>, on news that they're each <a href=\"https://us.spindices.com/documents/indexnews/announcements/20190624-948566/948566_mktxaaxnmlab546usna6xncr6.pdf?force_download=true\" target=\"_blank\">moving into the S&amp;P SmallCap 600 index</a>.</li>    <li>USANA is replacing Fidelity Southern (NASDAQ:<a href='https://seekingalpha.com/symbol/LION' title='Fidelity Southern Corporation'>LION</a>), which is set to be acquired by Ameris Bancorp. That move is effective before the open of trading Monday, July 1.</li>    <li>Meanwhile, Xencor is replacing HFF (NYSE:<a href='https://seekingalpha.com/symbol/HF' title='HFF, Inc.'>HF</a>), which is set to be acquired by Jones Lang LaSalle. That move is effective before the open on Tuesday, July 2.</li>    <li>In bigger index ripples, MarketAxess Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MKTX' title='MarketAxess Holdings Inc.'>MKTX</a>) is moving into the S&amp;P 500 to replace L3 Technologies (NYSE:<a href='https://seekingalpha.com/symbol/LLL' title='L3 Technologies, Inc.'>LLL</a>) set to be acquired by Harris. Replacing MarketAxess in the MidCap 400 is Axon Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/AAXN' title='Axon Enterprise, Inc.'>AAXN</a>), and replacing Axon in the SmallCap 600 is Mesa Laboratories (NASDAQ:<a href='https://seekingalpha.com/symbol/MLAB' title='Mesa Laboratories, Inc.'>MLAB</a>). Those moves are effective before Monday's open.</li>    <li>After hours, Axon is <font color=\"red\">down 1.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473421\" data-linked=\"USANA, Xencor get lift on entry to SmallCap 600\" data-tweet=\"$USNA $XNCR $LION - USANA, Xencor get lift on entry to SmallCap 600 https://seekingalpha.com/news/3473421-usana-xencor-get-lift-on-entry-to-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3473421-usana-xencor-get-lift-on-entry-to-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473419\" data-ts=\"1561411214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473419-cymabayplus-2_8-on-new-buy-rating-stifel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay +2.8% on new Buy rating at Stifel</a></h4><ul>    <li>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) is <font color=\"green\">up 2.8%</font> after Stifel starts it at Buy in an initiation of companies addressing nonalcoholic fatty liver disease.</li>    <li>Treatment approvals are still many months away, but the firm has set a price target of $14, implying 107% upside.</li>    <li>The vast majority of covering analysts <a href=\"https://seekingalpha.com/symbol/CBAY/ratings/sell-side-ratings\" target=\"_blank\">rate the stock a Buy</a>, while <a href=\"https://seekingalpha.com/symbol/CBAY/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha authors are Bullish</a> as well -- but the stock has a <a href=\"https://seekingalpha.com/symbol/CBAY/ratings/quant-ratings\" target=\"_blank\">Quant rating of Very Bearish</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473419\" data-linked=\"CymaBay +2.8% on new Buy rating at Stifel\" data-tweet=\"$CBAY - CymaBay +2.8% on new Buy rating at Stifel https://seekingalpha.com/news/3473419-cymabayplus-2_8-on-new-buy-rating-stifel?source=tweet\" data-url=\"https://seekingalpha.com/news/3473419-cymabayplus-2_8-on-new-buy-rating-stifel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473413\" data-ts=\"1561410256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTT\" target=\"_blank\">GTT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473413-gtt-slides-craig-hallum-pares-growth-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GTT slides as Craig-Hallum pares growth expectations</a></h4><ul>   <li>GTT (NYSE:<a href='https://seekingalpha.com/symbol/GTT' title='GTT Communications, Inc.'>GTT</a>) finished among top NYSE losers today, <font color=\"red\">down 12.6%</font>, after a still-optimistic Craig-Hallum trimmed its price target -- and expectations for when organic growth would return.</li>    <li>Analyst George Sutton cut his target to $40 from $45 but maintained a Buy rating on the stock; that target now implies 100% upside from today's close.</li>    <li>The firm had expected growth in Q2 and Q3 but now sees modest growth beginning in Q4. Even without a near-term catalyst, the stock's a \"significant opportunity\" over 12 months and beyond, he writes.</li>    <li>Meanwhile, while sell-side analysts <a href=\"https://seekingalpha.com/symbol/GTT/ratings/sell-side-ratings\" target=\"_blank\">rate the stock Outperform on average</a>, it has a <a href=\"https://seekingalpha.com/symbol/GTT/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Very Bearish</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473413\" data-linked=\"GTT slides as Craig-Hallum pares growth expectations\" data-tweet=\"$GTT - GTT slides as Craig-Hallum pares growth expectations https://seekingalpha.com/news/3473413-gtt-slides-craig-hallum-pares-growth-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3473413-gtt-slides-craig-hallum-pares-growth-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473412\" data-ts=\"1561409999\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDX\" target=\"_blank\">ALDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473412-aldeyra-up-12-after-hours-ahead-of-reproxalap-data-readout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aldeyra up 12% after hours ahead of reproxalap data readout</a></h4><ul><li>Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) will host a <a href=\"https://seekingalpha.com/pr/17553721-aldeyra-therapeutics-schedules-webcast-conference-call-announce-top-line-results-solace-trial\" target=\"_blank\">conference call</a> tomorrow, June 25, at 8:00 am ET to discuss topline results from the Phase 3 SOLACE trial evaluating topical ocular reproxalap in patients with noninfectious anterior uveitis.</li><li>Shares are up <font color=\"green\">12%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473412\" data-linked=\"Aldeyra up 12% after hours ahead of reproxalap data readout\" data-tweet=\"$ALDX - Aldeyra up 12% after hours ahead of reproxalap data readout https://seekingalpha.com/news/3473412-aldeyra-up-12-after-hours-ahead-of-reproxalap-data-readout?source=tweet\" data-url=\"https://seekingalpha.com/news/3473412-aldeyra-up-12-after-hours-ahead-of-reproxalap-data-readout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473406\" data-ts=\"1561409662\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KRYS\" target=\"_blank\">KRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473406-krystal-bio-initiates-100m-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Krystal Bio initiates $100M stock offering</a></h4><ul><li>Krystal Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/KRYS' title='Krystal Biotech, Inc.'>KRYS</a>) <a href=\"https://seekingalpha.com/pr/17553750-krystal-biotech-announces-proposed-100-million-public-offering-common-stock\" target=\"_blank\">commences </a>a $100M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473406\" data-linked=\"Krystal Bio initiates $100M stock offering\" data-tweet=\"$KRYS - Krystal Bio initiates $100M stock offering https://seekingalpha.com/news/3473406-krystal-bio-initiates-100m-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3473406-krystal-bio-initiates-100m-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473404\" data-ts=\"1561409514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARQL\" target=\"_blank\">ARQL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473404-arqule-files-for-mixed-shelf-and-stock-offering-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArQule files for mixed shelf and stock offering; shares down 3% after hours</a></h4><ul><li>ArQule (NASDAQ:<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1019695/000114420419032063/tv524098_s3asr.htm\" target=\"_blank\">prospectus </a>for an unspecified mixed shelf offering.</li><li>Not wasting any time, it launches a <a href=\"https://seekingalpha.com/pr/17553739-arqule-announces-commencement-proposed-public-offering-common-stock\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be released.</li><li>Shares are down <font color=\"red\">3%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473404\" data-linked=\"ArQule files for mixed shelf and stock offering; shares down 3% after hours\" data-tweet=\"$ARQL - ArQule files for mixed shelf and stock offering; shares down 3% after hours https://seekingalpha.com/news/3473404-arqule-files-for-mixed-shelf-and-stock-offering-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3473404-arqule-files-for-mixed-shelf-and-stock-offering-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473395\" data-ts=\"1561408551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EB\" target=\"_blank\">EB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473395-eventbrite-dips-on-stake-disclosure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eventbrite dips on stake disclosure</a></h4><ul><li>Foxhaven Asset Management <a href=\"https://seekingalpha.com/filing/4542325\" target=\"_blank\">reports </a>a 5.8% stake in Eventbrite (NYSE:<a href='https://seekingalpha.com/symbol/EB' title='Eventbrite, Inc.'>EB</a>).</li><li>EB shares are <font color=\"red\">down 0.7%</font> after hours to $16.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473395\" data-linked=\"Eventbrite dips on stake disclosure\" data-tweet=\"$EB - Eventbrite dips on stake disclosure https://seekingalpha.com/news/3473395-eventbrite-dips-on-stake-disclosure?source=tweet\" data-url=\"https://seekingalpha.com/news/3473395-eventbrite-dips-on-stake-disclosure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473384\" data-ts=\"1561407510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBRV\" target=\"_blank\">NBRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473384-ema-accepts-nabrivas-application-for-antibiotic-lefamulin-shares-up-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EMA accepts Nabriva&#39;s application for antibiotic lefamulin; shares up 6% after hours</a></h4><ul><li>Nabriva Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics plc'>NBRV</a>) is up <font color=\"green\">6%</font> after hours in reaction to its <a href=\"https://seekingalpha.com/pr/17553652-nabriva-therapeutics-announces-european-medicines-agency-ema-validation-marketing\" target=\"_blank\">announcement </a>that the European Medicines Agency &#40;EMA&#41; has accepted for review its marketing application for intravenous and oral formulations of lefamulin for the treatment of community-acquired pneumonia in adult patients.</li><li>The company expects an opinion from the advisory group CHMP in the next 12 - 15 months.</li><li>Its U.S. marketing applications are currently under FDA review with an action date of August 19.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473384\" data-linked=\"EMA accepts Nabriva&#39;s application for antibiotic lefamulin; shares up 6% after hours\" data-tweet=\"$NBRV - EMA accepts Nabriva&#39;s application for antibiotic lefamulin; shares up 6% after hours https://seekingalpha.com/news/3473384-ema-accepts-nabrivas-application-for-antibiotic-lefamulin-shares-up-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3473384-ema-accepts-nabrivas-application-for-antibiotic-lefamulin-shares-up-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473379\" data-ts=\"1561406805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRTX\" target=\"_blank\">MRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473379-mirati-launches-stock-offering-shares-down-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mirati launches stock offering; shares down 5% after hours</a></h4><ul><li>Mirati Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a>) slips <font color=\"red\">5%</font> after hours in reaction to its planned <a href=\"https://seekingalpha.com/pr/17553648-mirati-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473379\" data-linked=\"Mirati launches stock offering; shares down 5% after hours\" data-tweet=\"$MRTX - Mirati launches stock offering; shares down 5% after hours https://seekingalpha.com/news/3473379-mirati-launches-stock-offering-shares-down-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3473379-mirati-launches-stock-offering-shares-down-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473376\" data-ts=\"1561406538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473376-sally-beautyminus-17-after-amazon-beauty-move\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sally Beauty -17% after Amazon beauty move</a></h4><ul><li>The beauty store sector is being analyzed closely after Amazon swept in with a new initiative.</li><li>Jefferies <a href=\"https://seekingalpha.com/news/3473276-amazon-launches-beauty-store-professionals\" target=\"_blank\">warns</a> that almost a third of Sally Beauty Holdings' (<a href='https://seekingalpha.com/symbol/SBH' title='Sally Beauty Holdings, Inc.'>SBH</a> <font color='red'>-16.8%</font>) business is at risk of being impacted by Amazon's new pro beauty store concept.</li><li>The firm doesn't see the Amazon move as posing much of a risk for Ulta Beauty (<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a> <font color='red'>-2.6%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3473376\" data-linked=\"Sally Beauty -17% after Amazon beauty move\" data-tweet=\"$SBH $ULTA - Sally Beauty -17% after Amazon beauty move https://seekingalpha.com/news/3473376-sally-beautyminus-17-after-amazon-beauty-move?source=tweet\" data-url=\"https://seekingalpha.com/news/3473376-sally-beautyminus-17-after-amazon-beauty-move\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473369\" data-ts=\"1561405655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGCO\" target=\"_blank\">AGCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473369-shifting-farm-fundamentals-spur-agco-upgrade-jefferies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shifting farm fundamentals spur AGCO upgrade at Jefferies</a></h4><ul><li>AGCO (<a href='https://seekingalpha.com/symbol/AGCO' title='AGCO Corporation'>AGCO</a> <font color=\"green\">+2.5%</font>) shoots to a 52-week high after Jefferies <a href=\"https://thefly.com/thestreet/realmoney/index.php/AGCOid2925529/AGCO-Agco-upgraded-to-Buy-on-better-farm-fundamentals-at-Jefferies\" target=\"_blank\">upgrades shares to Buy</a> from Neutral, as analyst Stephen Volkmann believes shifting farm fundamentals support double-digit growth in North America and South America for 2020.</li><li>While maintaining a conservative margin outlook, Volkmann sees further upside from potentially higher margins as volumes build, raising his price target on AGCO to $90 from $70.</li><li>Volkmann <a href=\"https://seekingalpha.com/news/3473172-deere-upgraded-buy-jefferies\" target=\"_blank\">also upgraded</a> Deere (<a href='https://seekingalpha.com/symbol/DE' title='Deere & Company'>DE</a> <font color=\"green\">+1.6%</font>) to Buy, citing what he sees as a tightened global crop supply demand balance following five years of depressed large ag fundamentals.</li><li>DE's average <a href=\"https://seekingalpha.com/symbol/DE/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform, but both its <a href=\"https://seekingalpha.com/symbol/DE/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/DE/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Neutral.</li><li>AGCO's average <a href=\"https://seekingalpha.com/symbol/AGCO/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Hold while its <a href=\"https://seekingalpha.com/symbol/AGCO/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Very Bullish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473369\" data-linked=\"Shifting farm fundamentals spur AGCO upgrade at Jefferies\" data-tweet=\"$AGCO $DE - Shifting farm fundamentals spur AGCO upgrade at Jefferies https://seekingalpha.com/news/3473369-shifting-farm-fundamentals-spur-agco-upgrade-jefferies?source=tweet\" data-url=\"https://seekingalpha.com/news/3473369-shifting-farm-fundamentals-spur-agco-upgrade-jefferies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473358\" data-ts=\"1561402578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BT\" target=\"_blank\">BT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473358-uks-ee-fined-100k-for-violating-marketing-messages-rules\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UK&#39;s EE fined £100K for violating marketing messages rules</a></h4><ul>   <li>UK regulators have <a href=\"http://telecoms.com/498094/ee-feels-the-sharp-end-of-the-opt-in-stick/\" target=\"_blank\">fined EE</a>, the mobile unit of BT Group (<a href=\"http://seekingalpha.com/symbol/BT\" target=\"_blank\">BT</a> <font color=\"red\">-3.7%</font>), £100,000 for violating \"opt-in\" provisions governing direct marketing messages.</li>    <li>The company sent messages encouraging customers to use a new feature and suggesting device upgrades without permission, the Information Commissioner's office says.</li>    <li>\"Companies should be aware that texts and emails providing service information which also include a marketing or promotional element must comply with the relevant legislation or could face a fine up to £500,000,\" the regulator says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473358\" data-linked=\"UK&#39;s EE fined £100K for violating marketing messages rules\" data-tweet=\"$BT - UK&#39;s EE fined £100K for violating marketing messages rules https://seekingalpha.com/news/3473358-uks-ee-fined-100k-for-violating-marketing-messages-rules?source=tweet\" data-url=\"https://seekingalpha.com/news/3473358-uks-ee-fined-100k-for-violating-marketing-messages-rules\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473357\" data-ts=\"1561402231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473357-rtec-gtt-and-zm-among-notable-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RTEC, GTT and ZM among notable tech movers</a></h4><ul><li><strong>Gainers: </strong>VivoPower International (NASDAQ:<a href='https://seekingalpha.com/symbol/VVPR' title='VivoPower International PLC'>VVPR</a>) <font color=\"green\">+130%</font>. Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+17%</font>. Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"green\">+16%</font>. SigmaTron International (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMA' title='SigmaTron International, Inc.'>SGMA</a>) <font color=\"green\">+11%</font>. Rudolph Technologies (NYSE:<a href='https://seekingalpha.com/symbol/RTEC' title='Rudolph Technologies, Inc.'>RTEC</a>) <font color=\"green\">+10%</font>.</li> <li><strong>Losers: </strong>The9 (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"red\">-11%</font>. GTT Communications (NYSE:<a href='https://seekingalpha.com/symbol/GTT' title='GTT Communications, Inc.'>GTT</a>) <font color=\"red\">-10%</font>. Zoom Video Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ZM' title='Zoom Video Communications, Inc.'>ZM</a>) <font color=\"red\">-9%</font>. SCWorx (NASDAQ:<a href='https://seekingalpha.com/symbol/WORX' title='SCWorx Corp.'>WORX</a>) <font color=\"red\">-9%</font>. Foresight Autonomous Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473357\" data-linked=\"RTEC, GTT and ZM among notable tech movers\" data-tweet=\"$VVPR $RIOT $TCCO - RTEC, GTT and ZM among notable tech movers https://seekingalpha.com/news/3473357-rtec-gtt-and-zm-among-notable-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473357-rtec-gtt-and-zm-among-notable-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473355\" data-ts=\"1561401909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JMIA\" target=\"_blank\">JMIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473355-jumia-food-plans-cheaper-options-jmiaminus-1_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jumia Food plans cheaper options; JMIA -1.3%</a></h4><ul><li>The unit of Jumia Technologies (NYSE:<a href='https://seekingalpha.com/symbol/JMIA' title='Jumia Technologies AG'>JMIA</a>) <a href=\"https://www.reuters.com/article/us-jumia-ecommerce/jumia-food-looks-beyond-africas-middle-class-for-growth-idUSKCN1TP24L\" target=\"_blank\">will offer </a>cheaper menu options in its home market in hopes of boosting sales.</li><li>Jumia Food launched in 2012, primarily focusing on middle class residents who could afford internet. The rising use of smartphones and lowering costs of data in Africa has opened a wider market.</li><li>The platform's strategy includes working with restaurants to offer meals as cheap as about $2.95.</li><li>Last year, Uber launched the low-cost, quick-trip option Chap Chap for riders in Kenya in a similar bet.</li><li>Jumia Food has about 1M customers in 30 African cities with 4,000 restaurants on its platform.</li><li>JMIA shares are<font color=\"red\"> down 1.3%</font> to $25.29.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473355\" data-linked=\"Jumia Food plans cheaper options; JMIA -1.3%\" data-tweet=\"$JMIA - Jumia Food plans cheaper options; JMIA -1.3% https://seekingalpha.com/news/3473355-jumia-food-plans-cheaper-options-jmiaminus-1_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3473355-jumia-food-plans-cheaper-options-jmiaminus-1_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473354\" data-ts=\"1561401258\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OAS\" target=\"_blank\">OAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473354-expectations-for-oasis-midstream-too-optimistic-stanley-says-in-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Expectations for Oasis midstream too optimistic, Stanley says in downgrade</a></h4><ul><li>Oasis Petroleum (<a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color=\"red\">-5.5%</font>) plunges after Morgan Stanley <a href=\"https://thefly.com/thestreet/realmoney/index.php/OASid2925500/OAS-Oasis-Petroleum-downgraded-to-Equal-Weight-from-Overweight-at-Morgan-Stanley\" target=\"_blank\">downgrades</a> shares to Equal Weight from  Overweight with a $6 price target, cut from $7, citing a broad pullback in the group that has left most  of stocks in the sector trading at low multiples relative to history.</li><li>Stanley analyst Devin McDermott also says expectations for what OAS could receive if it pursues a midstream monetization could \"prove optimistic.\"</li><li>McDermott, who slightly reduced his outlook for oil prices and more meaningfully his price guidance for natural gas and natural gas liquids forecasts, <a href=\"https://seekingalpha.com/news/3473221-occidental-petroleum-cut-stanley-high-leverage-adds-oil-price-risk\" target=\"_blank\">also downgraded</a> Occidental Petroleum.</li><li>OAS' average <a href=\"https://seekingalpha.com/symbol/OAS/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform, while both its <a href=\"https://seekingalpha.com/symbol/OAS/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/OAS/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Bullish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473354\" data-linked=\"Expectations for Oasis midstream too optimistic, Stanley says in downgrade\" data-tweet=\"$OAS - Expectations for Oasis midstream too optimistic, Stanley says in downgrade https://seekingalpha.com/news/3473354-expectations-for-oasis-midstream-too-optimistic-stanley-says-in-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3473354-expectations-for-oasis-midstream-too-optimistic-stanley-says-in-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473341\" data-ts=\"1561399288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473341-sierra-metals-and-centrus-energy-among-energy-materials-gainers-ncs-multistage-and-forum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sierra Metals and Centrus Energy among Energy/Materials gainers; NCS Multistage and Forum Energy Technologies among losers</a></h4><ul><li><b>Gainers: </b>Sierra Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/SMTS' title='Sierra Metals Inc.'>SMTS</a>) <font color=\"green\">+12%</font>. Centrus Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a>) <font color=\"green\">+7%</font>. Seabridge Gold (NYSE:<a href='https://seekingalpha.com/symbol/SA' title='Seabridge Gold Inc.'>SA</a>) <font color=\"green\">+7%</font>. Gold Resource (NYSEMKT:<a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a>) <font color=\"green\">+6%</font>. PEDEVCO (NYSEMKT:<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>NCS Multistage (NASDAQ:<a href='https://seekingalpha.com/symbol/NCSM' title='NCS Multistage Holdings, Inc.'>NCSM</a>) <font color=\"red\">-9%</font>. Forum Energy Technologies (NYSE:<a href='https://seekingalpha.com/symbol/FET' title='Forum Energy Technologies, Inc.'>FET</a>) <font color=\"red\">-8%</font>. Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"red\">-7%</font>. Montage Resources (NYSE:<a href='https://seekingalpha.com/symbol/MR' title='Montage Resources Corporation'>MR</a>) <font color=\"red\">-7%</font>. Hecla Mining (NYSE:<a href='https://seekingalpha.com/symbol/HL' title='Hecla Mining Company'>HL</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473341\" data-linked=\"Sierra Metals and Centrus Energy among Energy/Materials gainers; NCS Multistage and Forum Energy Technologies among losers\" data-tweet=\"$SMTS $LEU $SA - Sierra Metals and Centrus Energy among Energy/Materials gainers; NCS Multistage and Forum Energy Technologies among losers https://seekingalpha.com/news/3473341-sierra-metals-and-centrus-energy-among-energy-materials-gainers-ncs-multistage-and-forum?source=tweet\" data-url=\"https://seekingalpha.com/news/3473341-sierra-metals-and-centrus-energy-among-energy-materials-gainers-ncs-multistage-and-forum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473339\" data-ts=\"1561399098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473339-stocks-waiver-amid-global-growth-concerns-easing-monetary-policy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks waiver amid global growth concerns, easing monetary policy</a></h4><ul><li>U.S. stocks erased much of the session's gains as investors consider the prospects of central banks easing monetary policy against worries about slower global economic growth.</li><li>The S&amp;P 500, which had been near its all-time closing high of 2,954.18, edged <font color=\"red\">down 0.1%</font> to 2,947.63 in midafternoon trading.</li><li>The Nasdaq <font color=\"red\">slips 0.2%</font> and the Dow struggles to hold onto <font color=\"green\">0.1% gain</font>.</li><li>Gold <font color=\"green\">jumps 1.3%</font> to $1,418.30 per ounce amid an expectation of lower Fed rates and geopolitical tensions between Iran and the U.S.</li><li>10-year Treasury rises, pushing yield down 4 basis points to 2.03%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473339\" data-linked=\"Stocks waiver amid global growth concerns, easing monetary policy\" data-tweet=\"Stocks waiver amid global growth concerns, easing monetary policy https://seekingalpha.com/news/3473339-stocks-waiver-amid-global-growth-concerns-easing-monetary-policy?source=tweet\" data-url=\"https://seekingalpha.com/news/3473339-stocks-waiver-amid-global-growth-concerns-easing-monetary-policy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473329\" data-ts=\"1561396951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HHC\" target=\"_blank\">HHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473329-howard-hughes-gets-250m-loan-for-seaport-redevelopment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Howard Hughes gets $250M loan for Seaport redevelopment</a></h4><ul><li>Howard Hughes Corp. (NYSE:<a href='https://seekingalpha.com/symbol/HHC' title='The Howard Hughes Corporation'>HHC</a>)<font color=\"red\"> slides 4.0% </font>after announcing it <a href=\"https://seekingalpha.com/pr/17552742-250m-financing-secured-seaport-district-redevelopment\" target=\"_blank\">obtained</a> a $250M term loan for the redevelopment of New York City's Seaport District.</li><li>The term loan has an initial rate of 6.10% for its first two years, followed by LIBOR + 4.10% with a LIBOR cap of 2.30%.</li><li>The interest-only loan is non-recourse subject to typical recourse carve-outs and prepayable after one year.</li><li>The loan is secured by a portion of HHC's Seaport District holdings, including Pier 17, the Tin Building, and various buildings in the district that are subject to the existing ground lease.</li><li>The Tin Building may be removed from the collateral after construction is complete without penalty.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473329\" data-linked=\"Howard Hughes gets $250M loan for Seaport redevelopment\" data-tweet=\"$HHC - Howard Hughes gets $250M loan for Seaport redevelopment https://seekingalpha.com/news/3473329-howard-hughes-gets-250m-loan-for-seaport-redevelopment?source=tweet\" data-url=\"https://seekingalpha.com/news/3473329-howard-hughes-gets-250m-loan-for-seaport-redevelopment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473325\" data-ts=\"1561396182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473325-u-s-global-investors-leads-financial-gainers-360-finance-and-flexshopper-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Global Investors leads financial gainers, 360 Finance and FlexShopper among losers</a></h4><ul><li><b>Gainers:</b> U.S. Global Investors (NASDAQ:<a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>) <font color=\"green\">+13%</font>. Scully Royalty (NYSE:<a href='https://seekingalpha.com/symbol/SRL' title='Scully Royalty Ltd.'>SRL</a>) <font color=\"green\">+11%</font>. Impac Mortgage Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/IMH' title='Impac Mortgage Holdings, Inc.'>IMH</a>) <font color=\"green\">+10%</font>. Innovative Industrial Properties (NYSE:<a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties, Inc.'>IIPR</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> 360 Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/QFIN' title='360 Finance, Inc.'>QFIN</a>) <font color=\"red\">-19%</font>. FlexShopper (NASDAQ:<a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a>) <font color=\"red\">-10%</font>. Realogy Holdings (NYSE:<a href='https://seekingalpha.com/symbol/RLGY' title='Realogy Holdings Corp.'>RLGY</a>) <font color=\"red\">-6%</font>. Golden Bull (NASDAQ:<a href='https://seekingalpha.com/symbol/DNJR' title='Golden Bull Limited'>DNJR</a>) <font color=\"red\">-5%</font>. Yintech Investment Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings Limited'>YIN</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473325\" data-linked=\"U.S. Global Investors leads financial gainers, 360 Finance and FlexShopper among losers\" data-tweet=\"$GROW $SRL $IMH - U.S. Global Investors leads financial gainers, 360 Finance and FlexShopper among losers https://seekingalpha.com/news/3473325-u-s-global-investors-leads-financial-gainers-360-finance-and-flexshopper-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473325-u-s-global-investors-leads-financial-gainers-360-finance-and-flexshopper-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473324\" data-ts=\"1561396136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473324-hydrogenics-and-rada-electronic-industries-among-industrial-gainers-armstrong-flooring-and-us\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hydrogenics and RADA Electronic Industries among industrial gainers; Armstrong Flooring and US Ecology among losers</a></h4><ul><li><b>Gainers: </b>NRC Group (NYSEMKT:<a href='https://seekingalpha.com/symbol/NRCG' title='NRC Group Holdings Corp.'>NRCG</a>) <font color=\"green\">+25%</font>. Comstock Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/CHCI' title='Comstock Holding Companies, Inc.'>CHCI</a>) <font color=\"green\">+8%</font>. RADA Electronic Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/RADA' title='RADA Electronic Industries Ltd.'>RADA</a>) <font color=\"green\">+6%</font>. Hydrogenics (NASDAQ:<a href='https://seekingalpha.com/symbol/HYGS' title='Hydrogenics Corporation'>HYGS</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Hebron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a>) <font color=\"red\">-9%</font>. US Ecology (NASDAQ:<a href='https://seekingalpha.com/symbol/ECOL' title='US Ecology, Inc.'>ECOL</a>) <font color=\"red\">-7%</font>. Shiloh Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/SHLO' title='Shiloh Industries, Inc.'>SHLO</a>) <font color=\"red\">-5%</font>. Armstrong Flooring (NYSE:<a href='https://seekingalpha.com/symbol/AFI' title='Armstrong Flooring, Inc.'>AFI</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473324\" data-linked=\"Hydrogenics and RADA Electronic Industries among industrial gainers; Armstrong Flooring and US Ecology among losers\" data-tweet=\"$NRCG $CHCI $RADA - Hydrogenics and RADA Electronic Industries among industrial gainers; Armstrong Flooring and US Ecology among losers https://seekingalpha.com/news/3473324-hydrogenics-and-rada-electronic-industries-among-industrial-gainers-armstrong-flooring-and-us?source=tweet\" data-url=\"https://seekingalpha.com/news/3473324-hydrogenics-and-rada-electronic-industries-among-industrial-gainers-armstrong-flooring-and-us\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473317\" data-ts=\"1561394911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473317-microcaps-mostly-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among midday movers</a></h4><ul><li><strong>Gainers: </strong>VivoPower International (NASDAQ:<a href='https://seekingalpha.com/symbol/VVPR' title='VivoPower International PLC'>VVPR</a>) <font color=\"green\">+108%</font>. Minerva Neurosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a>) <font color=\"green\">+43%</font>. PCM (NASDAQ:<a href='https://seekingalpha.com/symbol/PCMI' title='PCM, Inc.'>PCMI</a>) <font color=\"green\">+42%</font>. Krystal Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/KRYS' title='Krystal Biotech, Inc.'>KRYS</a>) <font color=\"green\">+30%</font>. NRC Group Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/NRCG' title='NRC Group Holdings Corp.'>NRCG</a>) <font color=\"green\">+26%</font>. India Globalization Capital (NYSEMKT:<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc.'>IGC</a>) <font color=\"green\">+21%</font>. Rekor Systems (REKR) <font color=\"green\">+20%</font>. Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+17%</font>. Del Frisco's Restaurant Group (NASDAQ:<a href='https://seekingalpha.com/symbol/DFRG' title='Del Frisco&#39;s Restaurant Group, Inc.'>DFRG</a>) <font color=\"green\">+17%</font>. VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a>) <font color=\"green\">+17%</font>.</li> <li><strong>Losers: </strong>Pier 1 Imports (NYSE:<a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports, Inc.'>PIR</a>) <font color=\"red\">-28%</font>. Avinger (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGR' title='Avinger, Inc.'>AVGR</a>) <font color=\"red\">-19%</font>. 360 Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/QFIN' title='360 Finance, Inc.'>QFIN</a>) <font color=\"red\">-19%</font>. Infrastructure and Energy Alternatives (NASDAQ:<a href='https://seekingalpha.com/symbol/IEA' title='Infrastructure and Energy Alternatives, Inc.'>IEA</a>) <font color=\"red\">-18%</font>. Akerna (NASDAQ:<a href='https://seekingalpha.com/symbol/KERN' title='Akerna Corp.'>KERN</a>) <font color=\"red\">-15%</font>. China SXT Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SXTC' title='China SXT Pharmaceuticals, Inc.'>SXTC</a>) <font color=\"red\">-14%</font>. Sally Beauty Holdings (NYSE:<a href='https://seekingalpha.com/symbol/SBH' title='Sally Beauty Holdings, Inc.'>SBH</a>) <font color=\"red\">-13%</font>. Mereo BioPharma Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MREO' title='Mereo BioPharma Group plc'>MREO</a>) <font color=\"red\">-13%</font>. Affimed N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed N.V.'>AFMD</a>) <font color=\"red\">-12%</font>. Precision BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/DTIL' title='Precision BioSciences, Inc.'>DTIL</a>) <font color=\"red\">-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473317\" data-linked=\"Microcaps mostly among midday movers\" data-tweet=\"$VVPR $NERV $PCMI - Microcaps mostly among midday movers https://seekingalpha.com/news/3473317-microcaps-mostly-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473317-microcaps-mostly-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473315\" data-ts=\"1561394671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRD\" target=\"_blank\">TLRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473315-tailored-brandsplus-14-after-dividend-maintained\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tailored Brands +14% after dividend maintained</a></h4><ul><li>Tailored Brands (<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a> <font color='green'>+13.7%</font>) rallies after the retailer keeps its $0.18 per share quarterly dividend in place.</li><li>There has been some speculation on Wall Street that Tailored Brands would cut the payout due to liquidity pressures.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473315\" data-linked=\"Tailored Brands +14% after dividend maintained\" data-tweet=\"$TLRD - Tailored Brands +14% after dividend maintained https://seekingalpha.com/news/3473315-tailored-brandsplus-14-after-dividend-maintained?source=tweet\" data-url=\"https://seekingalpha.com/news/3473315-tailored-brandsplus-14-after-dividend-maintained\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>100&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473312\" data-ts=\"1561393911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTN\" target=\"_blank\">PTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473312-palatin-and-amag-give-up-gains-after-feuerstein-rains-on-vyleesi-parade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palatin and AMAG give up gains after Feuerstein rains on Vyleesi parade</a></h4><ul><li>STAT's Adam Feuerstein has thrown a <a href=\"https://www.statnews.com/2019/06/24/vyleesi-approval-palatin/\" target=\"_blank\">bucket of cold water</a> on investors in Palatin Technologies (<a href='https://seekingalpha.com/symbol/PTN' title='Palatin Technologies, Inc.'>PTN</a> <font color=\"red\">-6.7%</font>) and AMAG Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a> <font color=\"red\">-5.4%</font>) after the <a href=\"https://seekingalpha.com/news/3473096-amag-plus-11_5-percent-palatin-plus-42_6-percent-fdas-vyleesi-approval\" target=\"_blank\">FDA nod</a> for female hypoactive sexual desire disorder med Vyleesi (bremelanotide injection) on Friday. Shares were up <font color=\"green\">39%</font> and <font color=\"green\">12%</font>, respectively, since then before retracing.</li><li>Mr. Feuerstein has been a long-term bear on the drug, questioning its efficacy and the fact that it is an injectable rather than a pill which may constrain demand.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473312\" data-linked=\"Palatin and AMAG give up gains after Feuerstein rains on Vyleesi parade\" data-tweet=\"$PTN $AMAG - Palatin and AMAG give up gains after Feuerstein rains on Vyleesi parade https://seekingalpha.com/news/3473312-palatin-and-amag-give-up-gains-after-feuerstein-rains-on-vyleesi-parade?source=tweet\" data-url=\"https://seekingalpha.com/news/3473312-palatin-and-amag-give-up-gains-after-feuerstein-rains-on-vyleesi-parade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473307\" data-ts=\"1561392394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BT\" target=\"_blank\">BT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473307-bt-groupminus-3_4-deutsche-bank-cuts-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BT Group -3.4% as Deutsche Bank cuts to Sell</a></h4><ul>   <li>BT Group (NYSE:<a href='https://seekingalpha.com/symbol/BT' title='BT Group plc'>BT</a>) is <font color=\"red\">off 3.4%</font> to its lowest point in three weeks after Deutsche Bank downgraded the stock to Sell, amid a number of factors it says will boost the risk premium on the stock.</li>    <li>That includes a catch-up of fiber building in the UK, the firm says, with more funded alt-fiber-to-the-home deployments and related pressure on Openreach wholesale revenues along with higher capital expenditure spending.</li>    <li>Deutsche Bank's Robert Grindle is expecting a dividend cut from next year as well. The stock has a yield (trailing 12 months) of 7.48%.</li>    <li>Other sell-side analysts rate it <a href=\"https://seekingalpha.com/symbol/BT/ratings/sell-side-ratings\" target=\"_blank\">Outperform on average</a>, while the stock has a <a href=\"https://seekingalpha.com/symbol/BT/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473307\" data-linked=\"BT Group -3.4% as Deutsche Bank cuts to Sell\" data-tweet=\"$BT - BT Group -3.4% as Deutsche Bank cuts to Sell https://seekingalpha.com/news/3473307-bt-groupminus-3_4-deutsche-bank-cuts-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3473307-bt-groupminus-3_4-deutsche-bank-cuts-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473305\" data-ts=\"1561392281\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOLD\" target=\"_blank\">GOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473305-gold-stocks-gain-futures-extend-six-year-highs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold stocks gain as futures extend six-year highs</a></h4><ul><li><a href=\"https://www.cnbc.com/2019/06/24/gold-jumps-1percent-to-fresh-high-now-at-levels-not-seen-since-august-2013.html\" target=\"_blank\">Gold adds to six-year highs</a>, on track for a fifth straight gain, as prospects of lower Federal Reserve rates and lingering geopolitical tensions between the U.S. and Iran fuel safe-haven buying; Comex gold <font color=\"green\">+1.2%</font> to $1,417.40/bbl.</li><li>ETF investors are moving back into gold, Commerzbank analysts say, as holdings of the SPDR Gold Trust jumped  4.6% on Friday from a day earlier, its <a href=\"https://www.cnbc.com/2019/06/24/gold-market-us-dollar-moves-middle-east-tensions-in-focus.html\" target=\"_blank\">biggest one-day percentage gain  since September 2008</a>.</li><li>Large  speculators sharply <a href=\"https://www.kitco.com/news/2019-06-24/Gold-Rally-Chased-By-Money-Managers.html\" target=\"_blank\">increased their bullish positioning</a> in gold futures for the  fourth straight week, the Commodity  Futures Trading Commission reports.</li><li>Gold holding above the psychologically important $1,400/oz. level is a  <a href=\"https://www.reuters.com/article/global-precious/precious-gold-climbs-towards-near-6-year-peak-on-dovish-cenbanks-u-s-iran-tensions-idUSL4N23V2DX\" target=\"_blank\">positive signal</a> for consolidation after last week's rally, says Carlo Alberto De Casa, chief analyst at ActivTrades.</li><li>Gold prices have climbed nearly 8% so far this month and more than $70/oz. just over the past week.</li><li>Precious metals equities are rallying again: <a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color=\"green\">+3.5%</font>, <a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color=\"green\">+3%</font>, <a href='https://seekingalpha.com/symbol/AEM' title='Agnico Eagle Mines Limited'>AEM</a> <font color=\"green\">+2.9%</font>, <a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a> <font color=\"green\">+2.9%</font>, <a href='https://seekingalpha.com/symbol/AUY' title='Yamana Gold Inc.'>AUY</a> <font color=\"green\">+2.2%</font>, <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color=\"green\">+2.1%</font>, <a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a> <font color=\"green\">+1.9%</font>, <a href='https://seekingalpha.com/symbol/NEM' title='Newmont Goldcorp Corporation'>NEM</a> <font color=\"green\">+1.6%</font>, <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color=\"green\">+1.5%</font>, <a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color=\"green\">+1.1%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>, <a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>, <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a>, <a href='https://seekingalpha.com/symbol/JNUG' title='Direxion Daily Junior Gold Miners Index Bull 3x Shares ETF'>JNUG</a>, <a href='https://seekingalpha.com/symbol/GGN' title='GAMCO Global Gold, Natural Resources & Income Trust'>GGN</a>, <a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/JDST' title='Direxion Daily Junior Gold Miners Index Bear 3x Shares ETF'>JDST</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='Aberdn Std Gold Shs'>SGOL</a>, <a href='https://seekingalpha.com/symbol/GOEX' title='Global X Gold Explorers ETF'>GOEX</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/SGDM' title='Sprott Gold Miners ETF'>SGDM</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/SGDJ' title='Sprott Junior Gold Miners ETF'>SGDJ</a>, <a href='https://seekingalpha.com/symbol/DGL' title='Inv DB Mul-Sec Shs Invesco DB Gold Fund'>DGL</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3473305\" data-linked=\"Gold stocks gain as futures extend six-year highs\" data-tweet=\"$GOLD $KGC $AEM - Gold stocks gain as futures extend six-year highs https://seekingalpha.com/news/3473305-gold-stocks-gain-futures-extend-six-year-highs?source=tweet\" data-url=\"https://seekingalpha.com/news/3473305-gold-stocks-gain-futures-extend-six-year-highs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>79&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473299\" data-ts=\"1561392193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFMD\" target=\"_blank\">AFMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473299-new-data-on-affimeds-lead-candidate-fails-to-excite-investors-shares-down-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New data on Affimed&#39;s lead candidate fails to excite investors, shares down 12%</a></h4><ul><li>Affimed (<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed N.V.'>AFMD</a> <font color=\"red\">-12%</font>) slumps on average volume in response to <a href=\"https://seekingalpha.com/pr/17552549-affimed-announces-clinical-data-update-lead-product-candidate-afm13-cd30-plus-lymphoma-icml\" target=\"_blank\">updated results</a> on lead candidate AFM13 in patients with CD30-positive lymphomas. The data were presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland.</li><li>Final results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02665650?term=NCT02665650&amp;rank=1\" target=\"_blank\">Phase 1b study</a> assessing the combination of AFM13 and Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a> <font color=\"green\">+1.2%</font>) Keytruda (pembrolizumab) in relapsed/refractory Hodgkin lymphoma showed an 88% objective response rate &#40;ORR&#41; (the ORR for Keytruda alone in Hodgkin lymphoma was 69% in the KEYNOTE-087 study), including a 42% complete response &#40;CR&#41; rate (determined by investigators). The CR rate was about double that for Keytruda alone (22% in KEYNOTE-087). ORR and CR were 85% (n=11/13) and 46%, respectively, in a subgroup of patients who failed to respond to Seattle Genetics' (<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a> <font color=\"red\">-0.9%</font>) Adcetris (brentuximab vedotin).</li><li>Estimated progression-free survival &#40;PFS&#41; at months 6 and 12 were 78% and 45%, respectively.</li><li>Updated data from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03192202?term=afm13&amp;rank=2\" target=\"_blank\">Phase 1b/2a study</a> of AFM13 in patients with relapsed/refractory CD30-positive lymphoma with skin lesions showed an ORR of 50% (n=5/10). Two of the responders had a treatment-resistant type of lymphoma called <a href=\"http://www.bloodjournal.org/content/95/7/2212?sso-checked=true\" target=\"_blank\">transformed mycosis fungoides</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473299\" data-linked=\"New data on Affimed&#39;s lead candidate fails to excite investors, shares down 12%\" data-tweet=\"$AFMD $MRK $SGEN - New data on Affimed&#39;s lead candidate fails to excite investors, shares down 12% https://seekingalpha.com/news/3473299-new-data-on-affimeds-lead-candidate-fails-to-excite-investors-shares-down-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3473299-new-data-on-affimeds-lead-candidate-fails-to-excite-investors-shares-down-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>93&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473302\" data-ts=\"1561392118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473302-ennis-and-tuniu-in-consumer-gainers-beyond-meat-and-pyxus-international-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ennis and Tuniu in consumer gainers; Beyond Meat and Pyxus International among losers</a></h4><ul><li><b>Gainers: </b>Ennis (NYSE:<a href='https://seekingalpha.com/symbol/EBF' title='Ennis, Inc.'>EBF</a>) <font color=\"green\">+9%</font>. Tuniu (NASDAQ:<a href='https://seekingalpha.com/symbol/TOUR' title='Tuniu Corporation'>TOUR</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"red\">-8%</font>. At Home Group (NYSE:<a href='https://seekingalpha.com/symbol/HOME' title='At Home Group Inc.'>HOME</a>) <font color=\"red\">-7%</font>. Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) <font color=\"red\">-7%</font>. Fuling Global (NASDAQ:<a href='https://seekingalpha.com/symbol/FORK' title='Fuling Global Inc.'>FORK</a>) <font color=\"red\">-6%</font>. Youngevity International (NASDAQ:<a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473302\" data-linked=\"Ennis and Tuniu in consumer gainers; Beyond Meat and Pyxus International among losers\" data-tweet=\"$EBF $TOUR $PYX - Ennis and Tuniu in consumer gainers; Beyond Meat and Pyxus International among losers https://seekingalpha.com/news/3473302-ennis-and-tuniu-in-consumer-gainers-beyond-meat-and-pyxus-international-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473302-ennis-and-tuniu-in-consumer-gainers-beyond-meat-and-pyxus-international-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473297\" data-ts=\"1561391732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMX\" target=\"_blank\">KMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473297-morgan-stanley-expects-momentum-continue-carmax\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley expects momentum at continue at CarMax</a></h4><ul> <li>Morgan Stanley keeps CarMax (<a href='https://seekingalpha.com/symbol/KMX' title='CarMax, Inc.'>KMX</a> <font color='red'>-3.4%</font>) lined up as its top pick in the auto dealer sector.</li> <li>\"KMX is up more than 40% since before FY 4Q19 earnings, and the stock may trade sideways during the omni channel roll out. However, a strong FY 4Q20 may serve as a catalyst, with momentum building into FY 2021 after the omni channel roll out,\" writes analyst Adam Jonas.</li> <li>MS hikes its price target on CarMax to $99 (16.5X the FY21 EPS estimate) and reiterates an Overweight rating.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473297\" data-linked=\"Morgan Stanley expects momentum at continue at CarMax\" data-tweet=\"$KMX - Morgan Stanley expects momentum at continue at CarMax https://seekingalpha.com/news/3473297-morgan-stanley-expects-momentum-continue-carmax?source=tweet\" data-url=\"https://seekingalpha.com/news/3473297-morgan-stanley-expects-momentum-continue-carmax\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473281\" data-ts=\"1561389674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473281-canopy-slips-another-3-on-margin-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canopy slips another 3% on margin concerns</a></h4><ul><li>Cannabis producer Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"red\">-2.8%</font>) slips on average volume. Shares have retreated almost <font color=\"red\">11%</font> since Friday when it <a href=\"https://seekingalpha.com/article/4271553-canopy-growth-corp-cgc-q4-2019-results-earnings-call-transcript\" target=\"_blank\">released </a>fiscal 2019 results (year ended 3/31/19).</li><li>Sales were up 191% to C$226.3M but investors appear disappointed with other fundamentals.</li><li>Cowen's Vivien Azer (Outperform/C$82) is \"not worried\" about the sequential declines in its recreational, medical and international segments (Q4 sales of C$60M was larger than the next five competitors combined) but is concerned with the third consecutive fiscal year of gross margin erosion.</li><li>BMO's Tamy Chen (Market Perform/C$60 from C$65) believes gross margin will improve in the coming quarters but is less confident with the potential revenue contribution from edibles and vapes and the company's ability to hit its C$1B run-rate guidance by the end of fiscal 2020, adding that operating expenses required to ramp manufacturing and processing could be higher than planned.</li><li>Related tickers: Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"red\">-4.4%</font>), Aurora Cannabis (<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"red\">-1%</font>), Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group Inc.'>CRON</a> <font color=\"red\">-3.3%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/MJ' title='ETFMG Alternative Harvest ETF'>MJ</a>, <a href='https://seekingalpha.com/symbol/SOIL' title='Global X Fertilizers/Potash ETF'>SOIL</a>, <a href='https://seekingalpha.com/symbol/ACT' title='AdvisorShares Vice ETF'>ACT</a>, <a href='https://seekingalpha.com/symbol/YOLO' title='AdvisorShares Pure Cannabis ETF'>YOLO</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3473281\" data-linked=\"Canopy slips another 3% on margin concerns\" data-tweet=\"$CGC $TLRY $ACB - Canopy slips another 3% on margin concerns https://seekingalpha.com/news/3473281-canopy-slips-another-3-on-margin-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3473281-canopy-slips-another-3-on-margin-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473284\" data-ts=\"1561389157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473284-qualcomm-facing-eu-fine-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm facing EU fine - Bloomberg</a></h4><ul><li>Update with more information:</li><li>The case focuses on the pricing of 3G modem chips, and the fine could come as soon as next month, according to <a href=\"https://www.bloomberg.com/news/articles/2019-06-24/qualcomm-faces-second-eu-fine-as-vestager-s-last-big-tech-target\" target=\"_blank\"><em>Bloomberg</em> sources</a>.</li><li>The fine would follow $1.13B penalty EU fine Qualcomm received last year for thwarting other Apple suppliers.</li><li>Original post: Qualcomm (<a href='https://seekingalpha.com/symbol/QCOM' title='QUALCOMM Incorporated'>QCOM</a> <font color=\"red\">-0.3%</font>) dips after <em>Bloomberg</em> reports the company faces an EU antitrust fine for predatory pricing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473284\" data-linked=\"Qualcomm facing EU fine - Bloomberg\" data-tweet=\"$QCOM - Qualcomm facing EU fine - Bloomberg https://seekingalpha.com/news/3473284-qualcomm-facing-eu-fine-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3473284-qualcomm-facing-eu-fine-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473277\" data-ts=\"1561388515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473277-minerva-neurosciences-leads-healthcare-gainers-avinger-and-affimed-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Minerva Neurosciences leads healthcare gainers; Avinger and Affimed among losers</a></h4><ul><li><b>Gainers: </b>Minerva Neurosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a>) <font color=\"green\">+49%</font>. Krystal Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/KRYS' title='Krystal Biotech, Inc.'>KRYS</a>) <font color=\"green\">+23%</font>. India Globalization Capital (NYSEMKT:<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc.'>IGC</a>) <font color=\"green\">+17%</font>. Prevail Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PRVL' title='Prevail Therapeutics Inc.'>PRVL</a>) <font color=\"green\">+9%</font>. Xynomic Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/XYN' title='Xynomic Pharmaceuticals Holdings, Inc.'>XYN</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Avinger (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGR' title='Avinger, Inc.'>AVGR</a>) <font color=\"red\">-18%</font>. China SXT Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SXTC' title='China SXT Pharmaceuticals, Inc.'>SXTC</a>) <font color=\"red\">-14%</font>. Affimed (NASDAQ:<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed N.V.'>AFMD</a>) <font color=\"red\">-11%</font>. Axovant Gene Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/AXGT' title='Axovant Gene Therapies Ltd.'>AXGT</a>) <font color=\"red\">-11%</font>. Motus GI Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings, Inc.'>MOTS</a>) <font color=\"red\">-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473277\" data-linked=\"Minerva Neurosciences leads healthcare gainers; Avinger and Affimed among losers\" data-tweet=\"$NERV $KRYS $IGC - Minerva Neurosciences leads healthcare gainers; Avinger and Affimed among losers https://seekingalpha.com/news/3473277-minerva-neurosciences-leads-healthcare-gainers-avinger-and-affimed-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473277-minerva-neurosciences-leads-healthcare-gainers-avinger-and-affimed-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473276\" data-ts=\"1561388259\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473276-amazon-launches-beauty-store-for-professionals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon launches beauty store for professionals</a></h4><ul> <li>The beauty sector is thrown a curveball after Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='red'>-0.4%</font>) Business announces the <a href=\"https://www.amazonbusinessblog.com/managing-purchasing/professional-beauty-products-now-available\" target=\"_blank\">launch</a> of the Amazon Professional Beauty Store.</li> <li>The e-commerce giant says the beauty concept for professionals will offer stylists, barbers and estheticians a convenient, custom shopping experience with great selection.</li><li>Some of the brands included are Wella Color Charm, RUSK, and OPI Professional.</li> <li>Names to watch off the development include Sally Beauty Holdings (<a href='https://seekingalpha.com/symbol/SBH' title='Sally Beauty Holdings, Inc.'>SBH</a> <font color='red'>-8.5%</font>), Ulta Beauty (<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a> <font color='red'>-3.8%</font>) and Revlon (<a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='red'>-3.2%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473276\" data-linked=\"Amazon launches beauty store for professionals\" data-tweet=\"$AMZN $SBH $ULTA - Amazon launches beauty store for professionals https://seekingalpha.com/news/3473276-amazon-launches-beauty-store-for-professionals?source=tweet\" data-url=\"https://seekingalpha.com/news/3473276-amazon-launches-beauty-store-for-professionals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473270\" data-ts=\"1561387720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EA\" target=\"_blank\">EA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473270-eaplus-2_6-stephens-calls-best-idea\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EA +2.6% as Stephens calls it best idea</a></h4><ul>   <li>Stephens has made Electronic Arts (<a href=\"http://seekingalpha.com/symbol/EA\" target=\"_blank\">EA</a> <font color=\"green\">+2.6%</font>) a \"best idea\" with the key catalyst the upcoming launch of <i>Apex Legends</i> season 2.</li>    <li><i>\"Fortnite's</i> popularity has hit a lull,\" analyst Jeff Cohen says of the battle-royale genre's leader, and EA's new season is \"launching at the right time to capture momentum.\"</li>    <li>The new season could generate $150M in revenue in a bull-case scenario, he says.</li>    <li>Sell-side analysts on average <a href=\"https://seekingalpha.com/symbol/EA/ratings/sell-side-ratings\" target=\"_blank\">rate EA an Outperform</a> and the stock has a <a href=\"https://seekingalpha.com/symbol/EA/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Bullish</a>, though Seeking Alpha authors are <a href=\"https://seekingalpha.com/symbol/EA/ratings/author-ratings#filter=all\" target=\"_blank\">Neutral on average</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473270\" data-linked=\"EA +2.6% as Stephens calls it best idea\" data-tweet=\"$EA - EA +2.6% as Stephens calls it best idea https://seekingalpha.com/news/3473270-eaplus-2_6-stephens-calls-best-idea?source=tweet\" data-url=\"https://seekingalpha.com/news/3473270-eaplus-2_6-stephens-calls-best-idea\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473269\" data-ts=\"1561387714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOOT\" target=\"_blank\">BOOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473269-boot-barn-rally-expected-to-continue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boot Barn rally expected to continue</a></h4><ul> <li>Cowen hikes its price target on Boot Barn (<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings, Inc.'>BOOT</a> <font color='green'>+4.1%</font>) to a Street-high <a href=\"https://twitter.com/CowenResearch\" target=\"_blank\">$42</a> as it becomes the latest firm to point to the \"Un-Amazon-Able\" nature of the Boot Barn business model.</li> <li>Also in the mix, analyst Oliver Chen sees Boot Barn's comparable sales shooting up 7% in Q1 to top the consensus expectation of +6%.</li> <li>Boot Barn is not only Outperform-rated across the sell-side community, the retailer also has a <a href=\"https://seekingalpha.com/symbol/BOOT/ratings/quant-ratings\" target=\"_blank\">Seeking Alpha Quant Rating</a> of Bullish.</li><li>Boot Barn printed a new high of $36.52 earlier in today's session.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473269\" data-linked=\"Boot Barn rally expected to continue\" data-tweet=\"$BOOT - Boot Barn rally expected to continue https://seekingalpha.com/news/3473269-boot-barn-rally-expected-to-continue?source=tweet\" data-url=\"https://seekingalpha.com/news/3473269-boot-barn-rally-expected-to-continue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473268\" data-ts=\"1561387674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IIIV\" target=\"_blank\">IIIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473268-btig-raises-i3-on-m-movement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BTIG raises i3 on M&amp;A movement</a></h4><ul><li>BTIG raises its i3 Verticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IIIV' title='i3 Verticals, Inc.'>IIIV</a>) target from $27 to $31 citing meetings with the company's management team.</li><li>Analyst Mark Palmer came away confident that i3's M&amp;A engine continues to move forward.</li><li>Palmer reiterates a Buy rating, which matches the company's average <a href=\"https://seekingalpha.com/symbol/IIIV/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>IIIV shares are <font color=\"green\">up 0.6%</font> to $27.12.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473268\" data-linked=\"BTIG raises i3 on M&amp;A movement\" data-tweet=\"$IIIV - BTIG raises i3 on M&amp;A movement https://seekingalpha.com/news/3473268-btig-raises-i3-on-m-movement?source=tweet\" data-url=\"https://seekingalpha.com/news/3473268-btig-raises-i3-on-m-movement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473267\" data-ts=\"1561387631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOLD\" target=\"_blank\">GOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473267-barricks-takeover-proposal-gets-sharp-pushback-from-acacia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barrick&#39;s takeover proposal gets sharp pushback from Acacia</a></h4><ul><li>Acacia Mining says it <a href=\"https://www.reuters.com/article/us-acacia-mining-m-a-barrick-gold/acacia-dismisses-barricks-view-on-miners-value-idUSKCN1TP1KS\" target=\"_blank\">strongly disagrees</a> with majority shareholder Barrick Gold's (<a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color=\"green\">+2.5%</font>) valuation of the company, particularly Barrick's view of its life of mine plans.</li><li>Barrick's share-for-share proposal last month valued Acacia at $787M, but Acacia says Barrick's proposal appears to have ignored the value of its portfolio of exploration and development assets.</li><li>Acacia also says Barrick's intervention in negotiations with the government of Tanzania, the length of time of Barrick's negotiations and the way the talks have been managed \"have had the effect of undermining Acacia in Tanzania.\"</li><li>However, a fair value buyout offer from Barrick would be attractive, Acacia adds.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473267\" data-linked=\"Barrick&#39;s takeover proposal gets sharp pushback from Acacia\" data-tweet=\"$GOLD $ABGLF $ABGLY - Barrick&#39;s takeover proposal gets sharp pushback from Acacia https://seekingalpha.com/news/3473267-barricks-takeover-proposal-gets-sharp-pushback-from-acacia?source=tweet\" data-url=\"https://seekingalpha.com/news/3473267-barricks-takeover-proposal-gets-sharp-pushback-from-acacia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473265\" data-ts=\"1561387379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WAB\" target=\"_blank\">WAB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473265-wabtecminus-5_4-on-downgrade-buckingham\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wabtec -5.4% on downgrade at Buckingham</a></h4><ul><li>Wabtec (NYSE:<a href='https://seekingalpha.com/symbol/WAB' title='Wabtec Corporation'>WAB</a>) starts the week <font color=\"red\">down 5.4%</font> after Buckingham analyst Matthew Brooklier downgraded the stock to Neutral from Buy and lowered his PT on shares to $81 (from $93).</li><li>He cited North American freight rail fundamentals being weaker than anticipated, as well as greater impact from Precision Scheduled Railroading efforts at multiple Class I rails.</li><li>Brooklier sees the possibility for these factors causing downward pressure in Wabtec's legacy Freight and GET operations, which could result in earnings disappointments over the next year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473265\" data-linked=\"Wabtec -5.4% on downgrade at Buckingham\" data-tweet=\"$WAB - Wabtec -5.4% on downgrade at Buckingham https://seekingalpha.com/news/3473265-wabtecminus-5_4-on-downgrade-buckingham?source=tweet\" data-url=\"https://seekingalpha.com/news/3473265-wabtecminus-5_4-on-downgrade-buckingham\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473262\" data-ts=\"1561387116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BURG\" target=\"_blank\">BURG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473262-chanticleer-holdings-rallies-after-adding-new-location-in-seattle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chanticleer Holdings rallies after adding a new location in Seattle</a></h4><ul> <li>Chanticleer Holdings (<a href='https://seekingalpha.com/symbol/BURG' title='Chanticleer Holdings, Inc.'>BURG</a> <font color='green'>+3.4%</font>) continues to expand in the Pacific Northwest.</li><li>The restaurant expects a soft opening of its newest Seattle Little Big Burger this weekend. The location is the company's third store in Seattle.</li>   <li>Source: <a href=\"https://seekingalpha.com/pr/17552888-chanticleer-holdings-plans-soft-opening-little-big-burger-green-lake-village-project-seattle\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3473262\" data-linked=\"Chanticleer Holdings rallies after adding a new location in Seattle\" data-tweet=\"$BURG - Chanticleer Holdings rallies after adding a new location in Seattle https://seekingalpha.com/news/3473262-chanticleer-holdings-rallies-after-adding-new-location-in-seattle?source=tweet\" data-url=\"https://seekingalpha.com/news/3473262-chanticleer-holdings-rallies-after-adding-new-location-in-seattle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473261\" data-ts=\"1561387067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473261-svmk-falls-after-medallias-100m-ipo-filing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SVMK falls after Medallia&#39;s $100M IPO filing</a></h4><ul><li>SVMK (<a href='https://seekingalpha.com/symbol/SVMK' title='SVMK Inc.'>SVMK</a> <font color='red'>-2.5%</font>) dips after Friday evening's news that competitor Medallia (<a href='https://seekingalpha.com/symbol/MDLA' title='Medallia'>MDLA</a>)<a href=\"https://www.sec.gov/Archives/edgar/data/1540184/000119312519178931/d727772ds1.htm\" target=\"_blank\"> filed</a> to go public.</li><li>The customer experience and feedback management platform had $337M in sales for the 12 months ending April 30, 2019.</li><li>The $200M figure is a placeholder. No pricing or other IPO terms were revealed in the filing.</li><li>Medallia hopes to list on the NYSE with the ticker \"MDLA\".</li></ul><div class=\"tiny-share-widget\" data-id=\"3473261\" data-linked=\"SVMK falls after Medallia&#39;s $100M IPO filing\" data-tweet=\"$SVMK $MDLA - SVMK falls after Medallia&#39;s $100M IPO filing https://seekingalpha.com/news/3473261-svmk-falls-after-medallias-100m-ipo-filing?source=tweet\" data-url=\"https://seekingalpha.com/news/3473261-svmk-falls-after-medallias-100m-ipo-filing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473255\" data-ts=\"1561386361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KRYS\" target=\"_blank\">KRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473255-krystal-biotech-up-27-on-positive-kb103-data-in-rare-skin-disorder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Krystal Biotech up 27% on positive KB103 data in rare skin disorder</a></h4><ul><li>Thinly traded Krystal Biotech (<a href='https://seekingalpha.com/symbol/KRYS' title='Krystal Biotech, Inc.'>KRYS</a> <font color=\"green\">+26.8%</font>) is up on more than triple normal volume, albeit on turnover of only 370K shares, on the heels of <a href=\"https://seekingalpha.com/pr/17552881-krystal-biotech-announces-positive-results-phase-2-clinical-trial-gemminus-2-study-kb103\" target=\"_blank\">positive data</a> from a Phase 2 clinical trial, GEM-2, evaluating topical gene therapy candidate KR103 in patients with a rare inherited skin disorder called dystrophic epidermolysis bullosa &#40;DEB&#41;.</li><li>Five of the six treated wounds (four recurring, two chronic) completely closed during the study. The one that failed to close completely was a chronic deep wound that has remained open for more than four years. It closed 42% at day 90 (the other chronic wound treated with KB103 closed completely by day 41). The average time to complete closure was 23.4 days.</li><li>The average duration of wound closure at day 90 (the most up-to-date time point) was 71 days. The duration of closure on the chronic wound that completely closed was 49 days.</li><li>The company will update investors on wound closure prior to launching a pivotal Phase 3 study, adding that preliminary results showed a duration of 101 days at the 120-day time point.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473255\" data-linked=\"Krystal Biotech up 27% on positive KB103 data in rare skin disorder\" data-tweet=\"$KRYS - Krystal Biotech up 27% on positive KB103 data in rare skin disorder https://seekingalpha.com/news/3473255-krystal-biotech-up-27-on-positive-kb103-data-in-rare-skin-disorder?source=tweet\" data-url=\"https://seekingalpha.com/news/3473255-krystal-biotech-up-27-on-positive-kb103-data-in-rare-skin-disorder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473254\" data-ts=\"1561386270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTRH\" target=\"_blank\">WTRH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473254-waitrplus-4_8-on-new-bull-rbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Waitr +4.8% on new bull at RBC</a></h4><ul><li>RBC starts Waitr (NASDAQ:<a href='https://seekingalpha.com/symbol/WTRH' title='Waitr Holdings Inc.'>WTRH</a>) with an Outperform rating and a $10 price target, implying an upside of 81%.</li><li>Waitr shares are<font color=\"green\"> up 4.8%</font> to $5.78.</li><li>WTRH has a Buy <a href=\"https://seekingalpha.com/symbol/WTRH/ratings/sell-side-ratings\" target=\"_blank\">average Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473254\" data-linked=\"Waitr +4.8% on new bull at RBC\" data-tweet=\"$WTRH - Waitr +4.8% on new bull at RBC https://seekingalpha.com/news/3473254-waitrplus-4_8-on-new-bull-rbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3473254-waitrplus-4_8-on-new-bull-rbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473253\" data-ts=\"1561386214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDS\" target=\"_blank\">DDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473253-dillards-seen-sailing-perfect-storm-to-rally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dillard&#39;s seen sailing into the perfect storm to rally</a></h4><ul> <li>Dillard's (<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s, Inc.'>DDS</a> <font color='red'>-2.2%</font>) is on watch after Mox Reports says shares could quickly <a href=\"https://moxreports.com/dillards-upside-perfect-storm/\" target=\"_blank\">double</a> with a bullish scenario setting up.</li> <li>\"Dillard\u2019s is now hitting another upside perfect storm like the one that last saw it spike up to the $90\u2019s. But this time I expect that the share price could double (or more). The share count is now much lower (higher intrinsic per share) and the float is now much tighter. In addition, David Einhorn already sold out at $75, such there is no longer the overhang of shares which had previously restrained the upward price spike,\" writes Richard Pearson on the department store operator.</li> <li>Pearson also notes that Dillard\u2019s consistently generates $300M to $500M of operating cash flow per year and has only 10M shares in the entire remaining float amid a high level of short interest.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473253\" data-linked=\"Dillard&#39;s seen sailing into the perfect storm to rally\" data-tweet=\"$DDS - Dillard&#39;s seen sailing into the perfect storm to rally https://seekingalpha.com/news/3473253-dillards-seen-sailing-perfect-storm-to-rally?source=tweet\" data-url=\"https://seekingalpha.com/news/3473253-dillards-seen-sailing-perfect-storm-to-rally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473248\" data-ts=\"1561385545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLS\" target=\"_blank\">NLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473248-nautilus-cfo-to-step-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nautilus CFO to step down</a></h4><ul> <li>Nautilus (<a href='https://seekingalpha.com/symbol/NLS' title='Nautilus, Inc.'>NLS</a> <font color='red'>-4.3%</font>) trades lower following the retirement of CFO Sidharth Nayar on July 12.</li> <li>The board expects to engage a search firm to help find a CFO replacement.</li> <li><a href=\"https://seekingalpha.com/filing/4540849\" target=\"_blank\">SEC Form 8-K</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3473248\" data-linked=\"Nautilus CFO to step down\" data-tweet=\"$NLS - Nautilus CFO to step down https://seekingalpha.com/news/3473248-nautilus-cfo-to-step-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3473248-nautilus-cfo-to-step-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473244\" data-ts=\"1561385080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473244-containerboard-pricing-anxiety-sends-sector-names-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Containerboard pricing anxiety sends sector names lower</a></h4><ul> <li>Packaging Corp of America (<a href='https://seekingalpha.com/symbol/PKG' title='Packaging Corporation of America'>PKG</a> <font color='red'>-2.5%</font>) and WestRock (<a href='https://seekingalpha.com/symbol/WRK' title='WestRock Company'>WRK</a> <font color='red'>-2%</font>) both trade lower after a Stephens <a href=\"https://seekingalpha.com/news/3473191-international-paper-minus-1-percent-stephens-warning\" target=\"_blank\">downgrade</a> on International Paper (<a href='https://seekingalpha.com/symbol/IP' title='International Paper Company'>IP</a> <font color='red'>-2.2%</font>) on pricing concerns turns some heads.</li> <li>Goldman Sachs is also negative on the sector following the latest pricing update from Pulp &amp; Paper Week, while BMO Capital thinks the low \"giveback\" on pricing is actually a positive given the higher level of inventory.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473244\" data-linked=\"Containerboard pricing anxiety sends sector names lower\" data-tweet=\"$PKG $WRK $IP - Containerboard pricing anxiety sends sector names lower https://seekingalpha.com/news/3473244-containerboard-pricing-anxiety-sends-sector-names-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3473244-containerboard-pricing-anxiety-sends-sector-names-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473240\" data-ts=\"1561384979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473240-alnylams-patisiran-shows-durable-effect-in-hattr-extension-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam&#39;s patisiran shows durable effect in hATTR extension study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17552643-alnylam-presents-new-onpattro-patisiran-results-2019-peripheral-nerve-society-annual-meeting\" target=\"_blank\">Results </a>from a global open-label extension study evaluating the long-term effects of Alnylam Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color=\"red\">-2.4%</font>) ONPATTRO (patisiran) in polyneuropathy of hereditary ATTR (hATTR) amyloidosis showed a sustained treatment benefit. The data were presented at the Peripheral Nerve Society Annual Meeting in Genoa, Italy.</li><li>At month 6, serum transthyretin levels dropped ~80% in patients in the placebo arm who switched to patisiran and were maintained over time. Patients on treatment for 30 - 36 months experienced sustained improvements in neuropathy impairment and quality-of-life &#40;QOL&#41; measures versus baseline.</li><li>A new analysis of the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT01960348?titles=apollo&amp;lead=alnylam&amp;phase=2&amp;rank=1\" target=\"_blank\">APOLLO </a>study showed that patients who were previously treated with Pfizer's (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"red\">-0.2%</font>) tafamidis (branded as Vyndaqel and Vyndamax) and received patisiran for 18 months showed significant improvements in polyneuropathy and QOL measures, on par with the overall study population.</li><li>The company also announced an indirect comparison between ONPATTRO and Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color=\"red\">-1.7%</font>) and Akcea Therapeutics' (<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics, Inc.'>AKCA</a> <font color=\"red\">-1.5%</font>) TEGSEDI (inotersen) that it says showed \"favorable treatment effects\" of patisiran.</li><li>The FDA approved ONPATTRO in August 2018 for the indication.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473240\" data-linked=\"Alnylam&#39;s patisiran shows durable effect in hATTR extension study\" data-tweet=\"$ALNY $PFE $IONS - Alnylam&#39;s patisiran shows durable effect in hATTR extension study https://seekingalpha.com/news/3473240-alnylams-patisiran-shows-durable-effect-in-hattr-extension-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3473240-alnylams-patisiran-shows-durable-effect-in-hattr-extension-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473238\" data-ts=\"1561384474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOG\" target=\"_blank\">HOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473238-steel-tariffs-to-remain-challenge-for-harley-davidson\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel tariffs to remain a challenge for Harley-Davidson</a></h4><ul> <li>Harley-Davidson (NYSE:<a href='https://seekingalpha.com/symbol/HOG' title='Harley-Davidson, Inc.'>HOG</a>) is <font color=\"red\">down 1.1%</font> after the Supreme Court rejected a challenge to the Trump Administration's steel tariffs.</li><li>The SCOTUS decision not to hear the case leaves in place a decision from the U.S. Court of International Trade from March.</li> <li>Harley was forced to move some production out of the U.S. to adjust to the higher steel tariffs enacted.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473238\" data-linked=\"Steel tariffs to remain a challenge for Harley-Davidson\" data-tweet=\"$HOG - Steel tariffs to remain a challenge for Harley-Davidson https://seekingalpha.com/news/3473238-steel-tariffs-to-remain-challenge-for-harley-davidson?source=tweet\" data-url=\"https://seekingalpha.com/news/3473238-steel-tariffs-to-remain-challenge-for-harley-davidson\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473237\" data-ts=\"1561384329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTN\" target=\"_blank\">RTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473237-raytheonminus-1-on-downgrade-buckingham\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raytheon -1% on downgrade at Buckingham</a></h4><ul><li>Buckingham analyst Richard Safran has <a href=\"https://rocklandregister.com/2019/06/24/raytheon-nysertn-stock-rating-reaffirmed-by-buckingham-research.html\" target=\"_blank\">downgraded</a> Raytheon (<a href='https://seekingalpha.com/symbol/RTN' title='Raytheon Company'>RTN</a> <font color=\"red\">-1%</font>) to Neutral from Buy and lowered his price target on shares to $195 (from $265).</li><li>Safran was initially neutral on the deal with United Technologies, which Buckingham does not cover, but now believes it is a solid deal for UTC that \"possibly undervalues\" Raytheon.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473237\" data-linked=\"Raytheon -1% on downgrade at Buckingham\" data-tweet=\"$RTN - Raytheon -1% on downgrade at Buckingham https://seekingalpha.com/news/3473237-raytheonminus-1-on-downgrade-buckingham?source=tweet\" data-url=\"https://seekingalpha.com/news/3473237-raytheonminus-1-on-downgrade-buckingham\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473236\" data-ts=\"1561384116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NYNY\" target=\"_blank\">NYNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473236-empire-resortsplus-8-after-kicking-off-strategic-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Empire Resorts +8% after kicking off strategic review</a></h4><ul> <li>Empire Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/NYNY' title='Empire Resorts, Inc.'>NYNY</a>) breaks higher after the casino operator  discloses that it retained Moelis &amp; Company to act as its financial advisor to evaluate strategic alternatives for the company as a whole.</li><li>The Empire board also created a special committee to oversee the evaluation of strategic alternatives for the company and disbanded its existing strategic development committee.</li><li>Shares of Empire Resorts are up 8.34% in early action.</li> <li><a href=\"https://seekingalpha.com/filing/4541778\" target=\"_blank\">SEC Form 8-K</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473236\" data-linked=\"Empire Resorts +8% after kicking off strategic review\" data-tweet=\"$NYNY - Empire Resorts +8% after kicking off strategic review https://seekingalpha.com/news/3473236-empire-resortsplus-8-after-kicking-off-strategic-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3473236-empire-resortsplus-8-after-kicking-off-strategic-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473232\" data-ts=\"1561383673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473232-firm-lowers-alphabet-on-eroding-search-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Firm lowers Alphabet on eroding Search growth</a></h4><ul><li>MoffettNathanson lowers its Alphabet (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a> <font color='red'>-0.7%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a> <font color='red'>-0.8%</font>) PT to $1,250 from $1,290.</li><li>The firm notes a \"concerning trend\" showing U.S. Search revenue growth has \"steadily\" eroded over the past several years, which was \"masked\" by revenue acceleration in other Google businesses, including YouTube and Cloud.</li><li>MoffettNathanson cites its analysis of Google's Economic Impact reports.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473232\" data-linked=\"Firm lowers Alphabet on eroding Search growth\" data-tweet=\"$GOOG $GOOGL - Firm lowers Alphabet on eroding Search growth https://seekingalpha.com/news/3473232-firm-lowers-alphabet-on-eroding-search-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3473232-firm-lowers-alphabet-on-eroding-search-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473225\" data-ts=\"1561382912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNX\" target=\"_blank\">ATNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473225-athenex-up-2-premarket-on-fda-sign-off-on-pegtomarginase-ind\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athenex up 2% premarket on FDA sign-off on pegtomarginase IND</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/17552700-athenex-announces-u-s-fda-allowance-investigational-new-drug-application-pt01-pegtomarginase\" target=\"_blank\">approved </a>Athenex's (NASDAQ:<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a>) IND for cancer candidate PT01 (pegtomarginase) contingent on the submission of certain updates to the filing.</li><li>Pegtomarginase is a genetically modified version of the enzyme arginase which depletes the amino acid arginine. The company plans to evaluate its potential as a cancer therapy since many tumor types need arginine to survive but lack the ability to synthesize it, adding that healthy cells that can produce arginine would be largely unaffected.</li><li>Shares are up <font color=\"green\">2%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473225\" data-linked=\"Athenex up 2% premarket on FDA sign-off on pegtomarginase IND\" data-tweet=\"$ATNX - Athenex up 2% premarket on FDA sign-off on pegtomarginase IND https://seekingalpha.com/news/3473225-athenex-up-2-premarket-on-fda-sign-off-on-pegtomarginase-ind?source=tweet\" data-url=\"https://seekingalpha.com/news/3473225-athenex-up-2-premarket-on-fda-sign-off-on-pegtomarginase-ind\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473223\" data-ts=\"1561382830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEET\" target=\"_blank\">MEET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473223-meetminus-4_8-apple-considers-app-ban-nyp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MEET -4.8% as Apple considers app ban - NYP</a></h4><ul><li>Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) shares <font color=\"red\">drop 4.8%</font> pre-market after a <a href=\"https://nypost.com/2019/06/21/apple-considers-meetme-app-ban-after-report-claims-its-riddled-with-prostitution/?utm_campaign=iosapp&amp;utm_source=twitter_app\" target=\"_blank\"><em>New York Post</em></a> article Friday evening suggested Apple is considering a MeetMe ban after accusations of prostitution on the app.</li><li>A private investigator submitted a report to Apple, which was then viewed by the Post.</li><li>The publication was also contacted by an unnamed short seller, who forwarded an email between an Apple app review employee and the investigator, which suggested an investigation into the app.</li><li>Meet Group's statement: \"We work hard to keep a safe environment on all of our mobile apps, and are in touch with law enforcement in cases when there are direct threats to physical safety. We are not aware of an ongoing investigation of the nature suggested in your message. We monitor the app 24 hours a day. We do not allow prostitution.\"</li><li>Related: Earlier this month, short seller The Friendly Bear <a href=\"https://seekingalpha.com/article/4270258-meet-group-monetization-explicit-live-cam-content-threatens-app-store-revenues\" target=\"_blank\">warned</a> that explicit content threatened MEET's app store revenues. Meet <a href=\"https://seekingalpha.com/news/3471543-meet-group-refutes-short-seller-report\" target=\"_blank\">refuted</a> the report, and Roth <a href=\"https://seekingalpha.com/news/3471784-meet-plus-4-percent-roth-refutes-short-seller-report\" target=\"_blank\">defended</a> the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473223\" data-linked=\"MEET -4.8% as Apple considers app ban - NYP\" data-tweet=\"$MEET - MEET -4.8% as Apple considers app ban - NYP https://seekingalpha.com/news/3473223-meetminus-4_8-apple-considers-app-ban-nyp?source=tweet\" data-url=\"https://seekingalpha.com/news/3473223-meetminus-4_8-apple-considers-app-ban-nyp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473220\" data-ts=\"1561382124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473220-riot-czr-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RIOT, CZR among premarket gainers</a></h4><ul><li>Minerva Neurosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a>) <font color=\"green\">+58%</font> on <a href=\"https://seekingalpha.com/news/3473159-minerva-3-percent-premarket-trading-halt\" target=\"_blank\">positive results</a> from a Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03375203?cond=insomnia+disorder&amp;lead=janssen&amp;phase=1&amp;rank=1\" target=\"_blank\">ISM2005</a>, evaluating seltorexant (MIN-202) in patients with insomnia disorder.</li><li>PCM (NASDAQ:<a href='https://seekingalpha.com/symbol/PCMI' title='PCM, Inc.'>PCMI</a>) <font color=\"green\">+42%</font> on being <a href=\"https://seekingalpha.com/news/3473128-insight-enterprises-acquire-pcm-35-share\" target=\"_blank\">acquired</a> by Insight.</li><li>Krystal Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/KRYS' title='Krystal Biotech, Inc.'>KRYS</a>) <font color=\"green\">+32%</font> on <a href=\"https://seekingalpha.com/pr/17552881-krystal-biotech-announces-positive-results-phase-2-clinical-trial-gemminus-2-study-kb103\" target=\"_blank\">positive results</a> from its Phase 2 placebo-controlled clinical trial of KB103 study and an update on results from Phase 1 study.</li><li>Palatin Technologies (NYSEMKT:<a href='https://seekingalpha.com/symbol/PTN' title='Palatin Technologies, Inc.'>PTN</a>) <font color=\"green\">+28%</font> as it <a href=\"https://seekingalpha.com/news/3473138-palatin-earns-60m-milestone-vyleesi-approval-u-s-shares-49-percent-premarket\" target=\"_blank\">earns $60M</a> milestone on Vyleesi approval in U.S.</li><li>Del Frisco's Restaurant (NASDAQ:<a href='https://seekingalpha.com/symbol/DFRG' title='Del Frisco&#39;s Restaurant Group, Inc.'>DFRG</a>) <font color=\"green\">+17%</font> on $650M <a href=\"https://seekingalpha.com/news/3473166-del-friscos-takes-650m-buyout\" target=\"_blank\">buyout</a>.</li><li>Caesars Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment Corporation'>CZR</a>) <font color=\"green\">+16%</font> on <a href=\"https://seekingalpha.com/news/3473133-eldorado-caesars-roll-dice-casino-merger\" target=\"_blank\">merger</a> with Eldorado Resorts.</li><li>India Globalization Capital (NYSEMKT:<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc.'>IGC</a>) <font color=\"green\">+9%</font>.</li><li>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a>) <font color=\"green\">+6%</font>.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+5%</font>.</li><li>China Jo-Jo Drugstores (NASDAQ:<a href='https://seekingalpha.com/symbol/CJJD' title='China Jo-Jo Drugstores, Inc.'>CJJD</a>) <font color=\"green\">+5% </font>as it enters into a strategic cooperation framework <a href=\"https://seekingalpha.com/pr/17552940-china-jo-jo-drugstores-enters-strategic-cooperation-framework-agreement-zhejiang-medical\" target=\"_blank\">agreement</a> with the Zhejiang Medical Insurance Bureau.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473220\" data-linked=\"RIOT, CZR among premarket gainers\" data-tweet=\"$NERV $PCMI $KRYS - RIOT, CZR among premarket gainers https://seekingalpha.com/news/3473220-riot-czr-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473220-riot-czr-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473217\" data-ts=\"1561381799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473217-eri-and-sdrl-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ERI and SDRL among premarket losers</a></h4><ul><li>Avinger (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGR' title='Avinger, Inc.'>AVGR</a>) <font color=\"red\">-10%</font>.</li><li>Eldorado Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/ERI' title='Eldorado Resorts, Inc.'>ERI</a>) <font color=\"red\">-9%</font> on <a href=\"https://seekingalpha.com/news/3473133-eldorado-caesars-roll-dice-casino-merger\" target=\"_blank\">merger</a> with Caesars Entertainment.</li><li>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"red\">-7%</font>.</li><li>ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473217\" data-linked=\"ERI and SDRL among premarket losers\" data-tweet=\"$AVGR $ERI $SDRL - ERI and SDRL among premarket losers https://seekingalpha.com/news/3473217-eri-and-sdrl-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473217-eri-and-sdrl-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473209\" data-ts=\"1561381226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473209-ubs-sees-22-upside-on-hostess-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS sees 22% upside on Hostess Brands</a></h4><ul> <li>UBS sees a favorable event path setting up for Hostess Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/TWNK' title='Hostess Brands, Inc.'>TWNK</a>) in the back half of the year and beyond.</li> <li>UBS on HosKtess share price drivers: \"First, Hostess sales trends are accelerating (per Nielsen data) as it launches new breakfast product lines &amp; regains shelf space at its largest customer (WMT is 21% of mix). Second, the recent acquisition of a Chicago Bakery facility, which had been poorly operated under prior ownership, brings Hostess new production capability in breakfast categories and a $40m EBITDA contribution bridge over 2 years (to +$25m in FY20 from -$15m in FY18). Third, TWNK is on pace to generate $350 -400m in FCF over three years.\"</li> <li>The firm <a href=\"https://www.cnbc.com/2019/06/24/calls-of-the-day-spotify-deere-dunkin-brands-more.html\" target=\"_blank\">upgrades</a> Hostess to a Buy rating from Neutral and assigns a price target of $17. The sell-side consensus on Hostess is at Outperform, while the <a href=\"https://seekingalpha.com/symbol/TWNK/ratings/quant-ratings\" target=\"_blank\">Seeking Alpha Quant rating</a> is Neutral.</li> <li>Shares of Hostess Brands are <font color=\"green\">up 1.44%</font> premarket to $14.09.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473209\" data-linked=\"UBS sees 22% upside on Hostess Brands\" data-tweet=\"$TWNK - UBS sees 22% upside on Hostess Brands https://seekingalpha.com/news/3473209-ubs-sees-22-upside-on-hostess-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3473209-ubs-sees-22-upside-on-hostess-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473199\" data-ts=\"1561379838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLK\" target=\"_blank\">SPLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473199-new-splunk-bull-praises-growth-drivers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Splunk bull praises growth drivers</a></h4><ul><li>Piper Jaffray starts Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) with an Overweight rating and $160 PT.</li><li>Analyst Andrew Nowinski cites SPLK's \"market leader\" position in security and IT operations. Nowinski sees \"a number of growth drivers, including a growing partner ecosystem, international expansion, and new products and deployment models.\"</li><li>Splunk shares are <font color=\"green\">up 1%</font> pre-market to $125.53.</li><li>SPLK has a Very Bullish <a href=\"https://seekingalpha.com/symbol/SPLK/ratings/quant-ratings?s=splk\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473199\" data-linked=\"New Splunk bull praises growth drivers\" data-tweet=\"$SPLK - New Splunk bull praises growth drivers https://seekingalpha.com/news/3473199-new-splunk-bull-praises-growth-drivers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473199-new-splunk-bull-praises-growth-drivers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473198\" data-ts=\"1561379837\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTX\" target=\"_blank\">UTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473198-united-techplus-1_1-after-upgrade-cowen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Tech +1.1% after upgrade at Cowen</a></h4><ul><li>Cowen analyst Cai von Rumohr <a href=\"https://www.marketwatch.com/story/united-technologies-stock-gains-after-cowen-upgrades-on-win-win-scenario-from-raytheon-merger-2019-06-24\" target=\"_blank\">upgrades</a> United Technologies (NYSE:<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a>) to Outperform from Market Perform, and raised his PT on shares to $150 (from $135), noting the proposed merger with Raytheon favors the Dow member.</li><li>The stock's decline since the deal's announcement \"offers a win-win for attractive standalone valuation or merger benefits,\" while the company's aerospace unit is at \"an attractive inflection point.\"</li><li>UTX <font color=\"green\">+1.1%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3473198\" data-linked=\"United Tech +1.1% after upgrade at Cowen\" data-tweet=\"$UTX - United Tech +1.1% after upgrade at Cowen https://seekingalpha.com/news/3473198-united-techplus-1_1-after-upgrade-cowen?source=tweet\" data-url=\"https://seekingalpha.com/news/3473198-united-techplus-1_1-after-upgrade-cowen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473197\" data-ts=\"1561379756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEIP\" target=\"_blank\">MEIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473197-mei-pharma-up-5-premarket-on-updated-meminus-401-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MEI Pharma up 5% premarket on updated ME-401 data</a></h4><ul><li>Thinly traded micro cap MEI Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/MEIP' title='MEI Pharma, Inc.'>MEIP</a>) is up <font color=\"green\">5% </font>premarket on light volume in response to <a href=\"https://seekingalpha.com/pr/17552421-mei-pharma-presents-updated-clinical-dataminus-401-phase-1b-study-patients-indolent-b-cell\" target=\"_blank\">updated results</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02914938?intr=me-401&amp;lead=mei+pharma&amp;rank=2\" target=\"_blank\">Phase 1b clinical trial</a> evaluating PI3K delta inhibitor ME-401, combined with Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding AG'>OTCQX:RHHBY</a>) Rituxan (rituximab) or BeiGene's (NASDAQ:<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene, Ltd.'>BGNE</a>) zanubrutinib, in patients with relapsed/refractory follicular lymphoma &#40;FL&#41; and relapsed/refractory lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The data were presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland.</li><li>The overall response rate was 83% (n=54/64), including a 100% response rate in CLL/SLL (n=14/14). The response rate in FL was 80% (n=40/50). Median progression-free survival &#40;PFS&#41; has not been reached.</li><li>On the safety front, the most common serious treatment-related adverse events were diarrhea/colitis (20% - continuous dosing, 10% - intermittent dosing) and pneumonia/pneumonitis (13% - continuous dosing, 3% - intermittent dosing).</li><li>A <a href=\"https://clinicaltrials.gov/ct2/show/NCT03768505?intr=me-401&amp;lead=mei+pharma&amp;rank=1\" target=\"_blank\">Phase 2 study</a> assessing ME-401 as monotherapy for the treatment of FL patients who have failed to respond to at least two prior lines of treatment is underway with an estimated primary completion date of December 2020. The primary endpoint is objective response rate over two years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473197\" data-linked=\"MEI Pharma up 5% premarket on updated ME-401 data\" data-tweet=\"$MEIP $BGNE $RHHBY - MEI Pharma up 5% premarket on updated ME-401 data https://seekingalpha.com/news/3473197-mei-pharma-up-5-premarket-on-updated-meminus-401-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3473197-mei-pharma-up-5-premarket-on-updated-meminus-401-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473193\" data-ts=\"1561379364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOP\" target=\"_blank\">SHOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473193-shopify-drops-roth-moves-cautious\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shopify drops as Roth moves cautious</a></h4><ul><li>Roth downgrades Shopify (NYSE:<a href='https://seekingalpha.com/symbol/SHOP' title='Shopify Inc.'>SHOP</a>) from Buy to Neutral but raises the PT from $275 to $300, implying a downside of 8%.</li><li>Last week, Shopify held its <a href=\"https://seekingalpha.com/news/3472425-shopify-plus-1_6-percent-unite-conference-launches\" target=\"_blank\">Unite conference</a> to positive reactions from the likes of <a href=\"https://seekingalpha.com/news/3472611-shopify-gets-new-street-high-target\" target=\"_blank\">Rosenblatt</a> and <a href=\"https://seekingalpha.com/news/3472681-oppenheimer-positive-shopifys-investor-day\" target=\"_blank\">Oppenheimer</a>.</li><li>SHOP shares are <font color=\"red\">down 0.8%</font> pre-market to $323.99.</li><li>Shopify has a Neutral <a href=\"https://seekingalpha.com/symbol/SHOP/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473193\" data-linked=\"Shopify drops as Roth moves cautious\" data-tweet=\"$SHOP - Shopify drops as Roth moves cautious https://seekingalpha.com/news/3473193-shopify-drops-roth-moves-cautious?source=tweet\" data-url=\"https://seekingalpha.com/news/3473193-shopify-drops-roth-moves-cautious\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>150&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473191\" data-ts=\"1561378879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IP\" target=\"_blank\">IP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473191-international-paperminus-1-after-stephens-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">International Paper -1% after Stephens warning</a></h4><ul> <li>International Paper (NYSE:<a href='https://seekingalpha.com/symbol/IP' title='International Paper Company'>IP</a>) dips in early trading after Stephens issues a downgrade on concerns over the uncertainty of containerboard pricing announcements.</li> <li>Stephens now has IP slotted at Equal Weight vs. the previous stance of Overweight and <a href=\"https://seekingalpha.com/symbol/IP/ratings/sell-side-ratings\" target=\"_blank\">consensus sell-side rating</a> of Outperform.</li> <li>Shares of International Paper are <font color=\"red\">down 0.88%</font> to $43.30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473191\" data-linked=\"International Paper -1% after Stephens warning\" data-tweet=\"$IP - International Paper -1% after Stephens warning https://seekingalpha.com/news/3473191-international-paperminus-1-after-stephens-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3473191-international-paperminus-1-after-stephens-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473186\" data-ts=\"1561378559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CZR\" target=\"_blank\">CZR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473186-icahn-backs-caesars-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Icahn backs Caesars deal</a></h4><ul> <li>Carl Icahn praises the board at Caesars Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment Corporation'>CZR</a>) for \"acting responsibly and decisively\" in negotiating and approving the transformational transaction with Eldorado Resorts.</li><li>The Caesars name isn't going anywhere following the deal. Upon completion of the transaction the combined casino operator will retain the Caesars name to capitalize on the value of the iconic global brand and its legacy of leadership in the global gaming industry.</li> <li>Shares of Caesars are <font color=\"green\">up 12.41%</font> premarket to $11.23, short of the $12.75 implied deal price due to the stock consideration.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3473133-eldorado-caesars-roll-dice-casino-merger\" target=\"_blank\">Eldorado, Caesars roll dice with casino merger</a> (June 24)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473186\" data-linked=\"Icahn backs Caesars deal\" data-tweet=\"$CZR - Icahn backs Caesars deal https://seekingalpha.com/news/3473186-icahn-backs-caesars-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3473186-icahn-backs-caesars-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473172\" data-ts=\"1561377420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DE\" target=\"_blank\">DE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473172-deere-upgraded-to-buy-jefferies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deere upgraded to Buy at Jefferies</a></h4><ul><li>Pointing to a tightened global crop supply demand balance following a half a decade of depressed agriculture fundamentals, Jefferies analyst Stephen Volkmann <a href=\"https://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Deere+%28DE%29+to+Buy/15637483.html\" target=\"_blank\">raised</a> Deere (NYSE:<a href='https://seekingalpha.com/symbol/DE' title='Deere & Company'>DE</a>) to Buy from Hold, with a $190 PT (from $150).</li><li>Additional upside? Positive momentum in farmer net income should support double-digit large equipment growth through 2020, he added, noting that his $12.00 earnings forecast is ahead of the consensus of $11.65.</li><li>DE <font color=\"green\">+1.1%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3473172\" data-linked=\"Deere upgraded to Buy at Jefferies\" data-tweet=\"$DE - Deere upgraded to Buy at Jefferies https://seekingalpha.com/news/3473172-deere-upgraded-to-buy-jefferies?source=tweet\" data-url=\"https://seekingalpha.com/news/3473172-deere-upgraded-to-buy-jefferies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473159\" data-ts=\"1561376102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NERV\" target=\"_blank\">NERV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473159-minerva-up-3-premarket-trading-halt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Minerva up 3% premarket before trading halt</a></h4><ul><li>Nasdaq has suspended trading in Minerva Neurosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a>) pending the release of news. Shares were up <font color=\"green\">3%</font> at the time.</li><li><strong>Update</strong>: The company just <a href=\"https://seekingalpha.com/pr/17552768-minerva-neurosciences-announces-achievement-primary-key-secondary-objectives-phase-2b\" target=\"_blank\">announced </a>positive results from a Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03375203?cond=insomnia+disorder&amp;lead=janssen&amp;phase=1&amp;rank=1\" target=\"_blank\">ISM2005</a>, evaluating seltorexant (MIN-202) in patients with insomnia disorder. The study met the primary endpoint of latency to persistent sleep &#40;LPS&#41; at night 1. Specifically, the mean decrease in LPS at night 1 was 30 minutes for the 5 mg dose, 50 minutes for the 10 mg dose and 48 minutes for the 20 mg dose versus 15 minutes for placebo.</li><li>Seltorexant is a selective orexin-<sub>2</sub> receptor antagonist. The orexin system in the brain plays a key role in modulating wakefulness, stress response and metabolism.</li><li>The study was conducted by development partner Janssen Pharmaceutica N.V.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li><li>Shares will resume trading at 8:00 am ET.</li><li><strong>Update</strong>: Shares are up <font color=\"green\">73%</font> premarket on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473159\" data-linked=\"Minerva up 3% premarket before trading halt\" data-tweet=\"$NERV - Minerva up 3% premarket before trading halt https://seekingalpha.com/news/3473159-minerva-up-3-premarket-trading-halt?source=tweet\" data-url=\"https://seekingalpha.com/news/3473159-minerva-up-3-premarket-trading-halt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473157\" data-ts=\"1561375941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473157-bristol-myers-opdivo-fails-to-beat-nexavar-in-liver-cancer-study-shares-down-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristol-Myers&#39; Opdivo fails to beat Nexavar in liver cancer study; shares down 3% premarket</a></h4><ul><li>A Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02576509?term=checkmate-459&amp;rank=1\" target=\"_blank\">CheckMate-45</a>9, evaluating Bristol-Myers Squibb's (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) Opdivo (nivolumab) compared to Bayer's (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer Aktiengesellschaft'>OTCPK:BAYRY</a>) <a href=\"https://www.nexavar-us.com/\" target=\"_blank\">Nexavar </a>(sorafenib) for the first-line treatment of unresectable hepatocellular carcinoma &#40;HCC&#41; <a href=\"https://seekingalpha.com/pr/17552632-bristol-myers-squibb-announces-results-checkmate-minus-459-study-evaluating-opdivo-nivolumab\" target=\"_blank\">failed to achieve the primary endpoint</a> of overall survival &#40;OS&#41;.</li><li>The trend in OS favored Opdivo but the separation from Nexavar, the current standard of care, was not statistically significant (p=0.0752).</li><li>Detailed results will be presented at a future medical conference.</li><li>Shares are down <font color=\"red\">3%</font> premarket in light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473157\" data-linked=\"Bristol-Myers&#39; Opdivo fails to beat Nexavar in liver cancer study; shares down 3% premarket\" data-tweet=\"$BMY $BAYRY - Bristol-Myers&#39; Opdivo fails to beat Nexavar in liver cancer study; shares down 3% premarket https://seekingalpha.com/news/3473157-bristol-myers-opdivo-fails-to-beat-nexavar-in-liver-cancer-study-shares-down-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3473157-bristol-myers-opdivo-fails-to-beat-nexavar-in-liver-cancer-study-shares-down-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473156\" data-ts=\"1561375767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXTA\" target=\"_blank\">AXTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473156-axalta-shares-advance-chairman-resigns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axalta shares advance as chairman resigns</a></h4><ul><li>Axalta (NYSE:<a href='https://seekingalpha.com/symbol/AXTA' title='Axalta Coating Systems Ltd.'>AXTA</a>) <font color=\"green\">climbs 6.7%</font> premarket after <a href=\"https://seekingalpha.com/pr/17552650-axalta-announces-board-changes\" target=\"_blank\">announcing</a> that Charlie Shaver resigned as chairman of its board of directors, effective June 30, 2019.</li><li>The board of directors appointed current Independent Presiding Director Mark Garrett as its new chairman. Garrett also serves as chairman of Axalta's Strategic Review Committee.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473156\" data-linked=\"Axalta shares advance as chairman resigns\" data-tweet=\"$AXTA - Axalta shares advance as chairman resigns https://seekingalpha.com/news/3473156-axalta-shares-advance-chairman-resigns?source=tweet\" data-url=\"https://seekingalpha.com/news/3473156-axalta-shares-advance-chairman-resigns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473154\" data-ts=\"1561375520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDD\" target=\"_blank\">DDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473154-3d-systemsplus-1-bear-hits-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3D Systems +1% as bear hits sidelines</a></h4><ul><li>B. Riley steps up to Neutral on 3D Systems (NYSE:<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corporation'>DDD</a>) from a Sell rating.</li><li>The price target is set at $8, an upside of 11%.</li><li>Last month, 3D <a href=\"https://seekingalpha.com/news/3460346-3d-systems-minus-11_6-percent-revenue-miss-demand-weakness\" target=\"_blank\">reported</a> a Q1 revenue miss due to shipment timing and demand weakness. The company planned to accelerate cost reductions.</li><li>3D shares are <font color=\"green\">up 1.2%</font> pre-market to $9.06.</li><li>DDD has a Hold average<a href=\"https://seekingalpha.com/symbol/DDD/ratings/sell-side-ratings\" target=\"_blank\"> Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473154\" data-linked=\"3D Systems +1% as bear hits sidelines\" data-tweet=\"$DDD - 3D Systems +1% as bear hits sidelines https://seekingalpha.com/news/3473154-3d-systemsplus-1-bear-hits-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3473154-3d-systemsplus-1-bear-hits-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473152\" data-ts=\"1561375398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473152-fedex-looks-to-boost-express-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx looks to boost Express volume</a></h4><ul> <li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) is <a href=\"https://www.wsj.com/articles/fedex-slashes-prices-to-fill-its-planes-11561332244\" target=\"_blank\">lowering</a> prices for some customers of its Express network in a bid to win more business away from UPS, according to sources.</li> <li>The company is said to be offering two-day air for same price as ground in an effort to boost volume for its Express network.</li> <li>FedEx's domestic Express business saw average revenue per package decline by 2% to $17.93 in FQ3 as a higher mix of lighter e-commerce packages factored in.</li> <li>Shares of FedEx are <font color=\"red\">down 0.82%</font> premarket to $164.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473152\" data-linked=\"FedEx looks to boost Express volume\" data-tweet=\"$FDX - FedEx looks to boost Express volume https://seekingalpha.com/news/3473152-fedex-looks-to-boost-express-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3473152-fedex-looks-to-boost-express-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473151\" data-ts=\"1561375311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CELG\" target=\"_blank\">CELG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473151-bristol-myers-to-divest-celgenes-otezla-to-get-ftc-blessing-on-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristol-Myers to divest Celgene&#39;s Otezla to get FTC blessing on merger</a></h4><ul><li>Aimed at getting timely sign-off from the U.S. Federal Trade Commission &#40;FTC&#41; on its planned takeover of Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>), Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) says it will <a href=\"https://seekingalpha.com/pr/17552631-bristol-myers-squibb-provides-update-pending-merger-celgene\" target=\"_blank\">divest</a> CELG's arthritis med <a href=\"https://www.otezla.com/\" target=\"_blank\">Otezla </a>(apremilast). It expects the merger to close by year-end or early 2020 (versus previous guidance of Q3).</li><li>Otezla accounted for ~10% of CELG's Q1 sales ($389M/4,025M).</li><li>Shares are up a fraction premarket.</li><li><strong>Update</strong>: CELG is down <font color=\"red\">4%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473151\" data-linked=\"Bristol-Myers to divest Celgene&#39;s Otezla to get FTC blessing on merger\" data-tweet=\"$CELG $BMY - Bristol-Myers to divest Celgene&#39;s Otezla to get FTC blessing on merger https://seekingalpha.com/news/3473151-bristol-myers-to-divest-celgenes-otezla-to-get-ftc-blessing-on-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3473151-bristol-myers-to-divest-celgenes-otezla-to-get-ftc-blessing-on-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>109&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473147\" data-ts=\"1561374834\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPOT\" target=\"_blank\">SPOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473147-spotifyminus-3-evercore-questions-q2-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spotify -3% as Evercore questions Q2 expectations</a></h4><ul><li>Evercore downgrades Spotify (NYSE:<a href='https://seekingalpha.com/symbol/SPOT' title='Spotify Technology S.A.'>SPOT</a>) from In-Line to Underperform and cuts the PT by $15 to $110.</li><li>Analyst Kevin Rippey cites <a href=\"https://seekingalpha.com/symbol/SPOT/earnings\" target=\"_blank\">expectations</a> for the Q2 print on August 1, saying that user and revenue estimates are possible, but the medium-term gross profit view seems unachievable.</li><li>Rippey also notes the more than 20% share rally from a low earlier in June.</li><li>Spotify shares are <font color=\"red\">down 3.1%</font> pre-market to $143.75.</li><li>SPOT has an Outperform Average <a href=\"https://seekingalpha.com/symbol/SPOT/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473147\" data-linked=\"Spotify -3% as Evercore questions Q2 expectations\" data-tweet=\"$SPOT - Spotify -3% as Evercore questions Q2 expectations https://seekingalpha.com/news/3473147-spotifyminus-3-evercore-questions-q2-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3473147-spotifyminus-3-evercore-questions-q2-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473146\" data-ts=\"1561374666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNKN\" target=\"_blank\">DNKN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473146-dunkin-brandsplus-1-after-wedbush-lift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dunkin&#39; Brands +1% after Wedbush lift</a></h4><ul> <li>Wedbush Securities upgrades Dunkin' Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/DNKN' title='Dunkin&#39; Brands Group, Inc.'>DNKN</a>) to an Outperform rating from Neutral on its view the restaurant chain's sales are at an inflection point.</li> <li>Same-store sales growth are seen accelerating as new menu and marketing initiatives begin to pay off.</li><li>Wedbush takes its price target all the way up to $92 to rep 16% upside potential. The 52-week high for DNKN is $81.40.</li> <li>Shares of Dunkin' are <font color=\"green\">up 1.01%</font> premarket to $80.34.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473146\" data-linked=\"Dunkin&#39; Brands +1% after Wedbush lift\" data-tweet=\"$DNKN - Dunkin&#39; Brands +1% after Wedbush lift https://seekingalpha.com/news/3473146-dunkin-brandsplus-1-after-wedbush-lift?source=tweet\" data-url=\"https://seekingalpha.com/news/3473146-dunkin-brandsplus-1-after-wedbush-lift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473145\" data-ts=\"1561374580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOR\" target=\"_blank\">MOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473145-morphosys-up-5-premarket-on-tafasitamab-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MorphoSys up 5% premarket on tafasitamab data</a></h4><ul><li>Thinly traded MorphoSys AG (NASDAQ:<a href='https://seekingalpha.com/symbol/MOR' title='MorphoSys AG'>MOR</a>) is up <font color=\"green\">5%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17552428-morphosys-presents-primary-analysis-data-l-mind-study-tafasitamab-mor208-combination\" target=\"_blank\">data </a>from a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02399085?term=l-mind&amp;rank=1\" target=\"_blank\">L-MIND</a>, evaluating tafasitamab (MOR208), combined with Celgene's (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) Revlimid (lenalidomide), in patients with relapsed/refractory diffuse large B cell lymphoma &#40;DLBCL&#41; who were ineligible for high-dose chemo and autologous stem cell transplantation. The results, <a href=\"https://seekingalpha.com/news/3464826-morphosys-lead-drug-successful-mid-stage-dlbcl-study\" target=\"_blank\">originally announced in May</a>, were presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland.</li><li>The trial met the primary endpoint of objective response rate &#40;ORR&#41;. Specifically, the ORR was 60% (n=48/80), including a complete response rate of 43% (n=34/80). Median progression-free survival &#40;PFS&#41; was 12.1 months (median follow-up of 17.3 months). Median overall survival &#40;OS&#41; was not reached. The OS rate at month 12 was 73.3%.</li><li>On the safety front, the most frequent serious or life-threatening treatment-emergent adverse events (TEAEs) were neutropenia (48%), thrombocytopenia (17%) and anemia (7%).</li><li>Tafasitamab is a monoclonal antibody that binds to a protein on the surface of B cells called CD19. The company is developing the product for the potential treatment of B cell malignancies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473145\" data-linked=\"MorphoSys up 5% premarket on tafasitamab data\" data-tweet=\"$MOR $CELG - MorphoSys up 5% premarket on tafasitamab data https://seekingalpha.com/news/3473145-morphosys-up-5-premarket-on-tafasitamab-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3473145-morphosys-up-5-premarket-on-tafasitamab-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473143\" data-ts=\"1561374341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473143-large-opening-for-encore-boston-harbor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Large opening for Encore Boston Harbor</a></h4><ul><li>The Encore Boston Harbor officially opened its doors yesterday to great fanfare and a massive crowd.</li><li>The resort owned by Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>) features a 210K-square-foot casino, 15 dining and lounge venues as well as 671 guest rooms and suites. The gaming space at the casino is larger than the space at the Encore and Wynn casinos in Las Vegas combined.</li> <li><a href=\"https://www.boston.com/news/local-news/2019/06/23/here-are-12-photos-from-the-grand-opening-of-encore-boston-harbor\" target=\"_blank\">Encore Boston photos</a></li>  <li>WYNN  <font color=\"green\">+2.67%</font> premarket to  $124.74.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17552458-encore-boston-harbor-now-open\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3473143\" data-linked=\"Large opening for Encore Boston Harbor\" data-tweet=\"$WYNN - Large opening for Encore Boston Harbor https://seekingalpha.com/news/3473143-large-opening-for-encore-boston-harbor?source=tweet\" data-url=\"https://seekingalpha.com/news/3473143-large-opening-for-encore-boston-harbor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473138\" data-ts=\"1561373245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTN\" target=\"_blank\">PTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473138-palatin-earns-60m-milestone-on-vyleesi-approval-in-u-s-shares-up-49-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palatin earns $60M milestone on Vyleesi approval in U.S.; shares up 49% premarket</a></h4><ul><li>Palatin Technologies (NYSEMKT:<a href='https://seekingalpha.com/symbol/PTN' title='Palatin Technologies, Inc.'>PTN</a>) is up <font color=\"green\">49%</font> premarket on robust volume on the <a href=\"https://seekingalpha.com/pr/17552350-fda-approves-new-drug-application-vyleesi-bremelanotide-injection\" target=\"_blank\">FDA nod</a> for HSDD med Vyleesi (bremelanotide injection). The action triggers a $60M milestone payment from licensee AMAG Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a>) (<font color=\"green\">+14%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3473138\" data-linked=\"Palatin earns $60M milestone on Vyleesi approval in U.S.; shares up 49% premarket\" data-tweet=\"$PTN $AMAG - Palatin earns $60M milestone on Vyleesi approval in U.S.; shares up 49% premarket https://seekingalpha.com/news/3473138-palatin-earns-60m-milestone-on-vyleesi-approval-in-u-s-shares-up-49-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3473138-palatin-earns-60m-milestone-on-vyleesi-approval-in-u-s-shares-up-49-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473133\" data-ts=\"1561372087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERI\" target=\"_blank\">ERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473133-eldorado-caesars-roll-dice-casino-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eldorado, Caesars roll dice with casino merger</a></h4><ul><li>It's official! U.S. casino operator Eldorado Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/ERI' title='Eldorado Resorts, Inc.'>ERI</a>) has agreed to <a href=\"https://seekingalpha.com/pr/17552569-eldorado-combine-caesars-creating-largest-owner-operator-u-s-gaming-assets\" target=\"_blank\">merge</a> with Caesars Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment Corporation'>CZR</a>) in a cash and stock deal that values its peer at $12.75 per share, or about $17.3B including debt.</li><li>The combined company's ownership will be split roughly between Eldorado and Caesars stakeholders, and follows reports that activist shareholder Carl Icahn looked more eager to sell than Caesars' board.</li><li>The tie-up also creates a more serious competitor to larger casino industry players, such as Las Vegas Sands (NYSE:<a href='https://seekingalpha.com/symbol/LVS' title='Las Vegas Sands Corp.'>LVS</a>), Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>) and MGM Resorts (NYSE:<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a>).</li><li>CZR <font color=\"green\">+16.6%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3473133\" data-linked=\"Eldorado, Caesars roll dice with casino merger\" data-tweet=\"$ERI $CZR $LVS - Eldorado, Caesars roll dice with casino merger https://seekingalpha.com/news/3473133-eldorado-caesars-roll-dice-casino-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3473133-eldorado-caesars-roll-dice-casino-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}